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CHAPTER I 
INTRODUCTION TO TUBEROUS SCLEROSIS COMPLEX AND mTOR 
SIGNALING 
 
Overview 
 
Tuberous sclerosis complex (TSC) is a multi-system developmental 
disorder found in approximately 1 in 6,000 people that affects the brain, kidney, 
skin, heart, and lungs (Crino, Nathanson, and Henske 2006; Curatolo, 
Bombardieri, and Jozwiak 2008; Osborne, Fryer, and Webb 1991). Affected 
organs have prominent hamartomas - benign focal lesions containing 
disorganized tissue that is related to the organ of origin. Hamartomas in TSC 
include shagreen patches and hypopigmented macules of the skin, 
angiomyolipomas of the kidney, and cortical tubers in the brain (Crino, 
Nathanson, and Henske 2006). Patients with TSC can have symptoms arising 
from dysfunction of any of these organ systems, but neurologic symptoms are 
usually most severe and include epilepsy, autism, and developmental delay. 
While the tuberous sclerosis complex was identified as a unique disease 
by clinical presentations more than 125 years ago, it was not until the last two 
decades that advances in genetics allowed the causative genes, TSC1 and 
TSC2, upstream regulators of the mechanistic target of rapamycin (mTOR) 
signaling pathway, to be identified (Bourneville 1880; van Slegtenhorst et al. 
1997; Consortium 1993). Much research has focused on the contribution of 
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dysregulated mTOR signaling in the pathogenesis of tuberous sclerosis. The 
protein products of TSC1 and TSC2 form a heterodimer to function as an 
inhibitor of mTOR complex 1 (mTORC1), a major signaling component in many 
cellular processes, including protein translation, metabolism, cell size regulation, 
cellular differentiation and tissue patterning. Current models of TSC propose a 
“two-hit hypothesis” for disease pathogenesis. In this manner, patients with TSC 
inherit a mutant copy of either TSC1 or TSC2. The current model predicts the 
generation of hamartomatous tissue in whichever organ systems there is a loss 
of heterozygosity at either the TSC1 or TSC2 loci. A somatic mutation in the 
remaining functional copy of either of these genes results in dysregulated mTOR 
signaling and subsequent hamartoma generation.  
 My primary research has been focused on how mutations in TSC1 or 
TSC2 result in tissue-specific pathologies characteristic of tuberous sclerosis 
complex. Specifically, I have explored the mechanisms of tissue-specific disease 
pathogenesis – with a loss of heterozygosity driving pathogenesis in the kidney 
and haploinsufficiency possibly driving pathogenesis in neural progenitor cells 
and neuronal tissues. Chapter I will provide a clinical context to the phenotypes 
seen in patients with TSC, focusing on the skin, kidney, and neurologic lesions 
characteristic of TSC. Chapter I will go on to provide background into the current 
understanding of the genetics and molecular mechanisms of dysregulated mTOR 
signaling and TSC. Finally I will describe the current model of TSC pathogenesis, 
following Knudson’s two-hit hypothesis while discussing current limitations of this 
canonical model. Chapter II will describe how the canonical two-hit model of 
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tuberous sclerosis complex is helpful in understanding the pathogenesis of 
kidney lesions in this disease. Evidence will be presented that supports 
increased mTORC1 signaling being responsible for cystogenesis in these 
patients, possibly through disruption of the primary cilium. Chapter III will 
demonstrate mTORC1-dependent phenotypes in heterozygous human stem cells 
derived from TSC patients. These phenotypes include increased pluripotency 
and cell survival in the absence of a second hit mutation – in contradiction to the 
classical model. Chapter IV will discuss the importance of these data for 
understanding a multisystem disease such as TSC as a collection of various 
tissue-specific pathogenic mechanisms. Chapter IV will highlight possible future 
directions and extension of this research to further understand the various 
disease manifestations of TSC. Finally, broader implications of this research to 
the pathogenesis of autism and epilepsy will be addressed. 
 
Clinical Manifestations of Tuberous Sclerosis Complex 
 
One of the first clinical descriptions of tuberous sclerosis complex was 
published in 1880 by the neurologist Désiré-Magloire Bourneville, who reported a 
patient with facial angiofibromas, epilepsy and severe developmental delay 
(Bourneville 1880). On autopsy, Dr. Bourneville identified many brain lesions that 
resembled “hard potatoes” in the brain, giving rise to the Latinized name of this 
disease, “tuberous sclerosis.” Additionally, this initial patient also exhibited hard 
white lesions on both kidneys. From this initial description, and the accumulation 
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of reports of other patients with similar symptoms, the most common signs of 
TSC were codified in 1908 by Heinrich Vogt into a useful diagnostic triad which 
included epilepsy, developmental delay, and facial angiofibromas (Vogt 1908). 
Vogt’s triad remained the standard of diagnosis for TSC for nearly 60 years. 
Diagnostic criteria were ultimately revised because, while each member of the 
triad alone was very common in TSC patients, the complete triad was present in 
fewer than one third of all patients (Lagos and Gomez 1967). The revised 
diagnostic criteria opted to focus on the signs of pathologic lesions in the organ 
systems, such as cortical tubers, rather than the symptoms these lesions cause, 
such as epilepsy (Table 1.1) (Roach, Gomez, and Northrup 1998; Roach and 
Sparagana 2004).  
 Of the pathologies present in TSC, neurological manifestations are highly 
prevalent and are usually the most concerning symptoms clinically. The most 
common brain lesions in TSC are cortical tubers, found in more than 90% of 
patients. These tubers contain disorganized atypical glial and neuronal cell types, 
usually with accompanying astrocytosis (Yates et al. 2011). Cortical tubers arise 
very early in brain development. Autopsies of aborted fetuses with TSC display 
cortical tubers at 19 weeks of gestation, indicating generation of these tubers 
during periods of neurogenesis and restructuring of the cortex (Park et al. 1997; 
Wei et al. 2002). Cortical tubers have blurred boundaries of the gray and white 
matter, irregular arrangement of neurons, diffuse astrocytosis and very large, 
poorly differentiated cells called “giant” cells (Mizuguchi and Takashima 2001). 
Within the cortical tubers reside individual cells that express markers of glia, 
4
  
 
 
Table 1.1 Diagnostic criteria for Tuberous Sclerosis Complex.  
TSC probability is divided into three categories based on these findings: 
Definite TSC: Either 2 major features or 1 major feature with 2 minor features 
Probable TSC: One major feature and one minor feature 
Possible TSC: Either 1 major feature or 2 or more minor features 
 
Adapted from (Roach, Gomez, and Northrup 1998) and (Roach and Sparagana 
2004) 
Category) Major)Criteria) Minor)Criteria)
Brain&
Glioneuronal&hamartomas&& Cerebral&white&matter&migration&lines&
Subependymal&nodules& Retinal&achromic&patch&
Subependymal&giant&cell&astrocytoma& &&
Skin&
Facial&angiofibromas&or&forehead&plaques& Confetti&skin&lesions&
Shagreen&patch& Gingival&fibromas&
Three&or&more&hypomelanotic&macules& &&
Ungula&or&periungual&fibromas& &&
Kidney& Renal&angiomyolipoma& Multiple&renal&cysts&
Other&
Cardiac&rhabdomyoma& Multiple&pits&in&dental&enamel&
Multiple&retinal&nodular&hamartomas& Hamartomatous&rectal&polyps&
Lymphangioleiomyomatosis& Nonrenal&hamartomas&
&& Bone&cysts&
5
immature neurons, and fully mature neurons, supportive of defects in cellular 
differentiation and maturation (Crino et al. 1996; Jozwiak, Jozwiak, and Skopinski 
2005; Ess et al. 2004). Typical characteristics of a cortical tuber are shown in 
Figure 1.1. Both the numbers of cortical tubers present, as well as the proportion 
of brain occupied by these lesions, have been correlated with the severity of 
neurological impairment (Goodman et al. 1997; Jansen et al. 2008). Having more 
than the median number of tubers is correlated with poor seizure control as well 
as moderate to severe cognitive impairment (Goodman et al. 1997). Patients with 
an increased tuber volume-to-brain ratio tend to have earlier onset of epilepsy 
and decreased cognitive functioning (Jansen et al. 2008). These cortical lesions 
are thought to be responsible for the most severe neurological phenotypes of 
TSC, including epilepsy, cognitive deficits, and autism (Ess 2009). 
 Of the neurological symptoms of TSC, epilepsy is the most prevalent, 
affecting up to 90% of patients (Yates et al. 2011; McClintock 2002). The majority 
of TSC patients (60%) will have a seizure in the first year of life and nearly all 
TSC patients who have a single seizure at some point in life will develop epilepsy 
(Webb, Fryer, and Osborne 1991; Chu-Shore et al. 2010). The epileptogenic foci 
can often be localized to one or more cortical tubers in these patients. In cases of 
medically intractable epilepsy, resection of the localizing tuber is frequently a 
successful treatment option (Koh et al. 2000; Jansen et al. 2005). Not all cortical 
tubers, however, are epileptogenic and conversely, abnormal EEG activity can 
sometimes also be seen from structurally normal areas adjacent to tubers in TSC 
patients. This suggests that histologically normal brain tissue may still behave 
6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Histological features of cortical tubers. (A) Tubers contain immature cells 
that stain for neuroprogenitor markers such as Pax6. Two such neurons are shown at 
the arrowheads. (B) Cortical tubers also display diffuse astrocytosis as shown through 
staining for GFAP, a marker of astrocytes. (C-D) Laminar patterning of the cortex 
through Tuj1 staining. Neurons lose their laminar organization in cortical tubers (D) as 
compared to normal brain tissue (C). (E) Large eosinophilic cells called “Giant” Cells are 
also characteristic of cortical tubers seen in TSC, shown at arrowheads. 
A B 
C D 
E 
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abnormally at the molecular level (Thiele 2010; Holmes and Stafstrom 2007; 
Chugani et al. 1998; Major et al. 2009). 
 While epilepsy is by far the most common neurological manifestation of 
TSC, cognitive deficits and autism are also seen in many patients. Cognitive 
deficits are found in 44-65% of TSC patients and are correlated with severity of 
epilepsy in these patients (Yates et al. 2011; Joinson et al. 2003). Furthermore, 
even in patients within the normal range of IQ, patients had on average 10-point 
lower scores compared to unaffected siblings (Joinson et al. 2003). Autistic 
behaviors are found in approximately 50% of TSC patients and are a major 
source of stress for TSC patient caregivers (Kopp, Muzykewicz et al. 2008). 
Apart from the neurological manifestations of TSC, renal pathologies are 
common and diverse. Renal manifestations of TSC include cysts, 
angiomyolipomas (AML) and rarely, renal cell carcinoma (RCC) (Washecka and 
Hanna 1991; O'Callaghan et al. 2004). AMLs occur in up to 70% of patients with 
TSC and cysts occur in approximately 30% of patients (O'Callaghan et al. 2004). 
Unlike brain lesions, which arise prenatally, many kidney lesions are not present 
at birth. By 10 years of age, however, 80% of TSC patients have detectable 
kidney lesions (Ewalt et al. 1998). Many of these lesions remain asymptomatic, 
but if these lesions progress to affect kidney function, defects are not usually 
seen until after the second decade of life. Although these lesions are most 
commonly benign, renal complications are the most common cause of TSC-
related mortality (Shepherd et al. 1991).  
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Angiomyolipomas, common in TSC, are renal hamartomas that are 
composed of disorganized arrangements of vasculature, smooth muscle, and 
adipocytes. Due to extensive vascularization of these hamartomas, rupture and 
bleeding is an important complication of AMLs. TSC patients with symptomatic 
AMLs often have flank pain and hematuria (Steiner et al. 1993). Rarely, if the 
rupture is particularly severe, a medical emergency called Wunderlich syndrome 
can occur. Large ruptures can cause hypovolemic shock and require immediate 
surgery to stop hemorrhaging (Moratalla 2009). 
Renal cysts are both common and generally asymptomatic in TSC. 
However, a small subset of patients with TSC will develop severe polycystic 
kidney disease (PKD) (van Slegtenhorst et al. 1997). These patients usually have 
detectible kidney lesions at birth and progress to renal failure by early adulthood 
(van Slegtenhorst et al. 1997; O'Callaghan et al. 2004). As described in Chapter 
II, these patients often have a large deletion in the TSC2 gene and occasional 
involvement of the neighboring polycystic kidney disease 1 (PKD1) gene. 
 Unlike neurological and renal pathologies, dermatologic manifestations 
are less concerning clinically, yet they are very useful diagnostically. 
Dermatologic manifestations are the most common signs of TSC and are seen in 
up to 98% of TSC patients (Webb, Fryer, and Osborne 1996). The most common 
skin manifestations of TSC include hypopigmented macules called ash-leaf spots, 
angiofibromas of the face, and raised areas of skin, usually on the lower back, 
called shagreen patches. Hypopigmented macules are often the earliest skin 
lesions identified. Shagreen patches typically appear later, often around 5 years 
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of age. Facial angiofibromas become more common during adolescence (Webb 
et al. 1996).  
  
Mutations in the TSC1 and TSC2 genes are causative for TSC 
 
Accurate documentation of TSC cases and the development of Vogt’s 
triad by the early 1900s lead to extensive pedigree analyses for TSC. The first 
familial case of TSC was identified in 1913 and suggested an autosomal 
dominant means of inheritance (Berg 1913). However, it was not until advances 
in molecular biology and genetics that the causative genes for TSC were 
identified. Linkage analyses identified two distinct loci causative for TSC 
(Janssen et al. 1991). The genes at these loci were subsequently cloned and 
named TSC1 and TSC2 (Consortium 1993; van Slegtenhorst et al. 1997). TSC1 
was the first gene identified. It is located at 9q34 and encodes a transcript of 
8.6kb that contains 23 exons. The second gene identified, TSC2, is located at 
16p13.3 and encodes a transcript of 5.5 kb that contains 41 exons. The protein 
products of TSC1 and TSC2 are hamartin and tuberin, respectively and have no 
homology to each other but function together as a heterodimer. Mutations of 
either gene are causative for TSC. In the current model, hamartin binds to tuberin, 
thus stabilizing the entire complex. Tuberin then mediates its function through 
activity of its GAP domain. The individual functions of these two proteins provides 
some rationale for both the types of mutations in each gene that result in TSC as 
well as the relative proportion of disease caused by each gene. With a functional 
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GAP domain, mutations at the TSC2 locus are more likely to inhibit function of 
the protein product and cause disease. Causative TSC2 mutations are most 
often nonsense mutations, large deletions and missense mutations (within the 
GAP domain) (Maheshwar et al. 1997). TSC1, encoding for a stabilizing protein, 
is less sensitive to missense mutations disrupting function, and of TSC patients 
with TSC1 mutations, most have nonsense mutations or small deletions resulting 
in a frameshift (Maheshwar et al. 1997). Of TSC patients with identifiable 
mutations, TSC1 mutations are found only in approximately 20% of TSC cases; 
the majority of TSC cases are caused by mutations in TSC2 (Jones et al. 1999). 
Generally patients with TSC2 mutations have more severe phenotypes than 
those with mutations in TSC1 (Jones et al. 1997). Up to 15-20% of clinically 
diagnosed patients do not have any identifiable TSC1 or TSC2 mutations 
(Sancak et al. 2005). Patients with unidentifiable mutations tend to have milder 
clinical phenotypes, and failure to detect mutation may be due to somatic 
mosaicim or mutations in non-coding yet important regulatory regions of these 
two genes (Kwiatkowska et al. 1999).  
 
The hamartin/tuberin complex and mTOR signaling 
 
The protein products of TSC1 and TSC2, hamartin and tuberin 
respectively, form a complex that regulates signaling through the mechanistic 
target of rapamycin (mTOR) kinase. The pathogenesis of TSC is thought mainly 
to result from the dysregulation of the mTOR kinase signaling pathway 
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secondary to mutations in upstream signaling components. The mTOR signaling 
pathway has been implicated in the regulation of many cellular processes, 
including cell growth, proliferation, motility, cell survival, gene transcription and 
protein synthesis (Inoki, Corradetti, and Guan 2005). mTOR, a serine/threonine 
kinase, mediates these functions with distinct protein binding partners. Two 
complexes containing mTOR have been well defined and have specific 
downstream targets. The mTOR-Raptor-mLST8/GβL complex, or mTOR 
complex 1 (mTORC1), signals through p70-S6 Kinase 1 (S6K1) and 4E-BP1, 
and mainly affects translational activity and autophagy (Tee and Blenis 2005). 
The mTOR-Rictor-GβL-mSin1 complex, or mTOR complex 2 (mTORC2), 
activates Akt and Protein Kinase Cα (PKCα) and affects cell proliferation and 
cytoskeletal architecture (Garcia-Martinez and Alessi 2008; Sarbassov et al. 
2004). Rapamycin, the chemical compound from which mTOR derives its name 
is a mTORC1 specific inhibitor. mTORC2, which contains Rictor (rapamycin 
insensitive companion of mTOR), is largely unaffected by rapamycin treatment 
(Jacinto et al. 2004). Raptor and Rictor appear to be mutually exclusive binding 
partners of mTOR, controlling substrate specificity as well as the sensitivity to 
rapamycin. In normal tissue, the hamartin/tuberin complex regulates mTOR 
signaling activity with negative regulation of mTORC1 and positive regulation of 
mTORC2 (Huang et al. 2009). 
Hamartin, a 140-kilodalton (kDa) protein, and tuberin, a 200-kDa protein 
with a C-terminal GTPase activating (GAP) domain, function together but are not 
homologous. Both proteins are ubiquitously expressed, although highest levels 
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are found in the brain, kidney, and heart (Plank et al. 1999). The hamartin/tuberin 
complex is an important signaling hub in the mTOR kinase signaling pathway 
and differential phosphorylation of the complex integrates cues from upstream 
signaling components responding to growth factors, stress, energy status, 
oxygen levels, and amino acid availability. Some of the upstream pathways that 
signal through the hamartin/tuberin complex include AKT, ERK, WNT, and Rag-
GTPases (Manning et al. 2002; Ma et al. 2005; Inoki et al. 2006; Kim, Goraksha-
Hicks et al. 2008). Growth factors and mitogen signaling usually cause increased 
mTORC1 activity through inhibition of the hamartin/tuberin complex. Insulin-like 
growth factors cause activation of Akt, which phosphorylates tuberin and 
inactivates its GAP domain (Manning et al. 2002; Inoki et al. 2002). Activation of 
the Ras/MAPK pathway also results in inhibitory tuberin phosphorylation by ERK. 
Phosphorylation by ERK causes the hamartin/tuberin heterodimer to dissociate 
and allows degradation of the individual proteins (Ma et al. 2005). Both of these 
inhibitory phosphorylation events of tuberin result in increased mTORC1 activity. 
During cellular stress, mTOR activity is generally decreased, partially due to 
augmentation of the inhibitory action of the hamartin/tuberin complex. In low 
glucose environments for example, AMPK phosphorylates tuberin to enhance its 
GAP domain activity (Inoki, Zhu, and Guan 2003). In hypoxic conditions, 
upregulation of REDD1 causes sequestered tuberin to be released and promotes 
hamartin/tuberin complex formation (DeYoung et al. 2008). Through stimulation 
of GAP domain function and promotion of hamartin/tuberin complex formation, 
cellular stress pathways can effectively inhibit mTORC1 activity. 
13
Classically, this heterodimer complex is thought to be functional 
throughout the cytoplasm, but more recently these two proteins have been 
recognized to preferentially locate to the Golgi apparatus, lysosome, nucleus, 
and basal body of the primary cilia (Wienecke et al. 1996; York, Lou, and Noonan 
2006; Hartman et al. 2009). Differential subcellular localization of these two 
components may be another way, in addition to differential phosphorylation, that 
convergent pathways integrate their signal through this complex to control mTOR 
output.  
 
mTOR Complex 1 (mTORC1) 
 
The upstream regulation and downstream targets of mTOR Complex 1 are 
the most thoroughly understood components of the mTOR signaling pathway. 
Upstream of mTORC1, hamartin binds and stabilizes tuberin by preventing 
ubiquitylation of the complex (Benvenuto et al. 2000). This stabilization allows the 
C-terminal GAP domain of tuberin to inhibit Ras homologue enriched in brain 
(RHEB). The hamartin/tuberin complex then induces the conversion of the active 
RHEB-GTP bound state to the inactive RHEB-GDP state. In its active state, 
RHEB is a potent stimulator of mTORC1. RHEB-GTP stimulates mTOR signaling 
through antagonistic binding of FKBP38, an endogenous inhibitor of mTOR 
activity (Bai et al. 2007). While the hamartin/tuberin complex GTPase activity 
stimulates a GTP-to-GDP transition and inhibits RHEB activity, there is no 
established guanine nucleotide exchange factor (GEF) for RHEB to reverse this 
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process. Regulation of the reactivation of RHEB is still poorly understood, but 
may be another important means of mTOR regulation. 
In normal cells, signals from growth factors, high nutrient availability, or 
other pathways converge as described earlier to trigger inhibition of the 
hamartin/tuberin complex, allowing mTORC1 stimulation by RHEB and 
subsequent activation of cellular processes that result in increased cell growth 
and metabolism. The two most studied substrates of mTORC1, p70-S6 Kinase 1 
(S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), both help 
regulate protein translational machinery (von Manteuffel et al. 1997; Hara et al. 
1998). Phosphorylation of S6K1 by mTORC1 results in downstream 
phosphorylation of 40S ribosomal protein S6 (S6), eukaryotic elongation factor 2 
kinase, and a 80-kDa nuclear cap binding protein, the combination of which 
causes the recruitment of ribosomal machinery (Khaleghpour et al. 1999). 
Phosphorylation of 4E-BP1 by mTORC1 disrupts 4E-BP1 binding to mRNA. Free 
mRNA can then bind eukaryotic initiation factor 4G (eIF4G) and recruit the 
translational machinery activated by S6K1 (Hara et al. 1997). Therefore, both of 
these targets of mTORC1 cooperatively work to increase cellular protein 
translation. 
While mTORC1 signaling has the greatest effect on translation, there are 
many other downstream targets of this complex. mTORC1 inhibits activation of 
autophagy through phosphorylation of ULK1, a protein that plays a role in the 
formation of autophagic vesicles (Jung et al. 2009). mTORC1 also stimulates de 
novo lipid biogenesis and membrane formation through a PPAR-γ dependent 
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mechanism (Laplante and Sabatini 2009). Activation of mTORC1 promotes 
lipogenesis in response to insulin signaling (Li, Brown, and Goldstein 2010). 
mTORC1 signaling also influences cellular proliferation and survival. Increased 
lipid biogenesis and increased translation are prerequisites for normal cell 
proliferation; increased mTORC1 activity provides both new membrane for cell 
division and the ribosomal machinery needed for cell growth prior to mitosis. It 
has also been shown that the phosphorylation of the two main downstream 
targets of mTORC1, S6K1 and 4E-BP1, is required for G1 phase progression and 
cell cycle control (Fingar et al. 2004). mTORC1 activity has also been shown to 
increase levels of cyclins A, D1, and E causing cells to progress more quickly 
through the cell cycle (Ito and Rubin 1999; Tapon et al. 2001; Vadlakonda, 
Pasupuleti, and Pallu 2013). While mTORC1 signaling has been most closely 
associated with translation, effects are seen across other critical cellular 
processes. 
Rapamycin, the drug from which the mechanistic target of rapamycin 
derives its name, is an mTORC1-specific inhibitor. Rapamycin is a highly 
selective agent that has minimal off-target effects even at concentrations 10 to 
20-fold greater than the levels normally used to completely inhibit mTORC1 in 
cell culture assays (Davies et al. 2000). Rapamycin binds FK506-binding protein 
of 12 kDa (FKBP12) (Brown et al. 1994). The FKBP12-rapamycin complex can 
then cooperatively bind mTOR, restricting access to mTORC1 substrates and 
propagation of mTOR signaling (Yang et al. 2013). Furthermore FKBP12-
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Rapamycin can also sequester mTOR, preventing assembly of mTORC1 (Oshiro 
et al. 2004). 
 
mTOR Complex 2 (mTORC2) 
 
mTOR can also interact with Rictor to form a second complex that is 
rapamycin-insensitive and is not regulated through RHEB activity. The upstream 
regulation and downstream targets of mTORC2 are much less well understood 
than those of mTORC1. There is evidence that the hamartin/tuberin complex can 
directly bind and positively regulate mTORC2 (Huang et al. 2009). This is in 
direct contrast to the negative regulation of the hamartin/tuberin complex on 
mTORC1. However, control of mTORC2 independent of the hamartin/tuberin 
complex has also been described, mainly downstream of the phosphoinositide-3 
kinase/Akt pathway (Dalle Pezze et al. 2012). While mTORC1 downstream 
targets mainly include protein translational control, mTORC2 is thought to 
regulate the actin cytoskeleton and therefore cellular morphology (Jacinto et al. 
2004). The two main downstream targets of mTORC2 are Akt and protein kinase 
Cα (PKCα). mTORC2 phosphorylates Akt, priming Akt for further activation 
through other pathways. This allows interesting and complicated feedback loops, 
as Akt signaling is upstream of both mTORC1 and mTORC2 activity (Sarbassov 
et al. 2005). mTORC2 stimulation of PKCα and reorganization of the actin 
cytoskeleton is thought to largely underlie the effect of mTORC2 on cellular 
structure (Sarbassov et al. 2004).  
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Current model of TSC pathogenesis 
 
 Current models of TSC suggest a mechanism akin to Knudson’s two-hit 
hypothesis. In this model initially used to explain the pathogenesis of 
retinoblastoma, an individual inherits a single mutant copy of a tumor suppressor 
gene. A malignancy occurs when there is a somatic mutation, or “second hit,” in 
the functioning copy of the gene, resulting in a loss of heterozygosity of that 
tumor suppressor gene (Knudson 1971). Applied to tuberous sclerosis complex, 
a patient inherits a mutation in either the TSC1 or TSC2 genes. The location and 
timing of a loss of heterozygosity event in an individual progenitor cell determines 
where the characteristic lesions of TSC manifest. For example, if a second hit is 
somatically acquired in a neuroprogenitor population, a cortical tuber forms, while 
a second hit in epidermal cells would result in a shagreen patch. In this model, 
loss of heterozygosity at either the TSC1 or TSC2 loci would result in the 
absence of the hamartin/tuberin heterodimer. This leads to dysregulated mTOR 
signaling, specifically hyperactivation of mTORC1 and downregulation of 
mTORC2 (Figure 1.2). Most work has focused on the role of hyperactivation of 
mTORC1 in the pathogenesis of hamartomatous tissue in TSC. Consistent with 
this model, loss of heterozygosity has been identified in many hamartomas, as 
well as hyperactivation of mTORC1 as detected by hyperphosphorylation of 
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downstream mTORC1 targets (Sepp, Yates, and Green 1996; El-Hashemite et al. 
2003). This loss of heterozygosity has been repeatedly identified in renal and 
  
 
 
 
Figure 1.2 Schematized view of the canonical model of mTOR signaling in 
both healthy and hamartomatous tissue. In normal tissue, TSC1/TSC2 
function together to regulate mTOR activity. In current models of TSC, loss of 
heterozygosity of either TSC1 or TSC2 results in the loss of the heterodimer 
complex and subsequent hyperactivation of mTORC1. 
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lung manifestations of TSC (Henske et al. 1997; Cai et al. 2010). Additionally, 
microdissection of these lesions shows the same acquired somatic mutation in all 
cell types found in the hamartoma, indicating a clonal origin for these tumors 
(Niida et al. 2001). Finally, in samples from renal and lung manifestations, there 
is clear loss of protein expression of either hamartin or tuberin, confirming the 
loss of heterozygosity in human lesions. The high rate of detectable second hits, 
clonal origin, loss of protein product, and hyperactivation of mTORC1 signaling 
all support the two-hit hypothesis as a mechanism for TSC pathogenesis. 
 While the two-hit hypothesis has found much support in non-neuronal 
tissue, in cortical tubers – the putative cause for the most debilitating symptoms 
of the disease – second hits have long been undetectable (Henske et al. 1996; 
Niida et al. 2001). Even with current sequencing techniques, second hits are 
rarely observed. Whole tuber DNA extraction and sequencing fail to identify 
acquired mutations. In one of the few reports of detected loss of heterozygosity in 
cortical tuber samples, identification of a second mutation was achieved through 
laser dissection of single giant cells from the tuber and then pooling these cells 
together for sequencing (Crino et al. 2010). These giant cells are electrically 
silent when studied ex vivo (Cepeda, Andre, Vinters et al. 2005; Cepeda, Andre, 
Flores-Hernandez et al. 2005). This suggests that they are not the primary 
electrical cause of seizures and other neurological manifestations in TSC. 
However, even if these very rare acquired mutations play a role in the 
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pathogenesis of TSC, this is a much different mechanism in hamartoma 
formation in the brain than in the clonal hamartomas seen in the lungs and 
kidneys. In cortical tubers, it appears that the vast majority of cells in the 
hamartomatous lesion are heterozygous for either TSC1 or TSC2. This suggests 
two possible mechanisms for tuber pathogenesis. First, there could be non-cell-
autonomous effects of loss of heterozygosity in the small subset of giant cells 
with a detected acquired somatic mutation. In this hypothesis, the rare 
occurrences of second hits result, not in a clonal expansion as seen in kidney 
and lung lesions, but, in foci which signal to otherwise normally appearing 
heterozygous cells. These heterozygous cells would then develop abnormally in 
response to signals from the nearby giant cell that has had a loss of 
heterozygosity. This results in localized disorganization during the differentiation 
and migration of these progenitors, leading to the pathologic cortical tubers seen 
in patients. In the second possibility, neuronal tissue is uniquely sensitive to 
alterations in hamartin and tuberin levels. In this case, haploinsufficiency of either 
TSC1 or TSC2 results in minor signaling changes due to a dosage change in 
either hamartin or tuberin. Neuronal tissue may then be uniquely sensitive to 
minor alterations in mTOR signaling. Unlike in the renal and lung lesions, in this 
model, loss of both alleles in the brain may then not be necessary for hamartoma 
pathogenesis. Further supporting haploinsufficiency as a mechanism for neural 
pathogenesis are clinical observations, where abnormal EEG activity can be 
seen from structurally normal areas of the brain that do not contain giant cells. 
These areas, therefore, should not be affected by non-cell-autonomous effects 
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from this cell population with acquired second hits. (Thiele 2010; Holmes and 
Stafstrom 2007; Chugani et al. 1998). Cortical tubers can also be electrically 
silent while the adjacent tissue is hyperexcitable (Major et al. 2009). Additionally, 
in patients without clear focal lesions in the brain, otherwise structurally normal 
tissue still can display metabolic abnormalities suggestive of axonal dysfunction 
and demyelination. Combined, these data suggest that histologically normal brain 
tissue, without a loss of heterozygosity, may still behave abnormally at the 
molecular level. 
The presence of two very different mechanisms for the pathogenesis of 
TSC-associated lesions in different tissues presents challenges for relevant 
modeling of the disease. Furthermore, comparing patients with TSC and animal 
models is problematic due to species-specific pathologies. In rodent models of 
TSC, animals with heterozygous deletions of the Tsc1 or Tsc2 genes have far 
lower rates of non-neuronal lesions than that seen in humans, and brain 
pathologies such as cortical tubers are almost non-existent. The earliest model of 
TSC is the Eker rat, a spontaneously arising rodent model that features an 
inactivating mutation of the Tsc2 gene (Yeung et al. 1994). The pathologies seen 
in this model are strikingly different than those seen in human patients. While 
Eker rats almost never have cortical tubers, they have nearly 100% penetrance 
for bilateral renal cell carcinoma, a finding that is incredibly rare in human 
patients (Hino et al. 1994). To model cortical tubers specifically, it is necessary to 
inactivate both copies of either Tsc1 or Tsc2. Conventional knockouts for Tsc1 
and Tsc2 are embryonic lethal (Rennebeck et al. 1998). To circumvent this 
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species-specific obstacle, tissue-specific knockouts of either Tsc1 or Tsc2 have 
been generated in mice using Cre-Lox recombination. For example, two 
complementary models that have been used to understand the role of mTOR 
signaling during neurodevelopment are dorsal and ventral forebrain-specific 
knockouts of Tsc1 (Carson et al. 2012; Fu et al. 2012). Reminiscent of the 
human disease, these models show atypical giant cells, cortical dyslamination, 
and decreased seizure thresholds. These models, however, contain large 
numbers of cells lacking both copies of Tsc1, and the disorganization observed is 
found throughout the entirety of the cortex, in direct contrast to the heterozygous 
and focal nature of cortical tubers in humans. While conditional knockouts are 
required to observe cortical lesions in mice, recent evidence suggests that even 
heterozygous rodents may have subtle learning deficits and increased sensitivity 
to epilepsy. Eker rats, heterozygous for Tsc2, have no cortical tubers present, yet 
demonstrate abnormal episodic learning and increased sensitivity to repeat 
chemical induction of seizures (Waltereit et al. 2006). Heterozygous Tsc2 rats 
also display decreased long-term potentiation, long-term depression, and 
synaptic plasticity in the hippocampus (von der Brelie et al. 2006). These very 
subtle defects in heterozygous rodents are still not as severe nor do they exhibit 
the variety of symptoms as seen in TSC patients. Therefore, heterozygous 
rodent models under-represent the neurological phenotypes of TSC2 mutation. 
Conditional knockouts for Tsc1 or Tsc2, while closer approximations to the 
human phenotype, arise from a loss of heterozygosity not detected in human 
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brain tissue. These limitations of rodent models reveal the need for new ways to 
explore cortical pathogenesis in TSC.  
Rodent models, while insufficient to understand the pathogenesis of 
cortical tubers, are excellent for understanding non-neuronal phenotypes of TSC. 
Non-neuronal lesions in TSC are clearly due to clonal expansion of progenitor 
cells following a loss of heterozygosity at either TSC1 or TSC2. Tissue-specific 
knockout of either of these genes can mimic the pathogenesis of a variety of 
lesions. Common TSC-associated lesions of the heart, lung and kidney 
manifestations have all been well modeled using these methods and have shown 
that disease pathogenesis is due to dysregulated mTOR signaling (Meikle et al. 
2005; Prizant et al. 2013; Armour, Carson, and Ess 2012).  
My work demonstrates how dysregulated mTOR signaling contributes to 
the tissue specific phenotypes seen in tuberous sclerosis complex. In Chapter II, 
I will show how the canonical two-hit model is instructive to understanding the 
pathogenesis of kidney disease in TSC. Here I provide evidence that loss of 
either Tsc1 or Tsc2 in a rodent model results in cystogenesis in an mTORC1- but 
not mTORC2-dependent process. Additionally I will provide evidence that 
increased mTORC1 activity alters primary cilia, providing a mechanistic link 
between altered mTOR signaling and a known mediator of renal cystogenesis. In 
Chapter III, I will highlight both the limitations of the canonical two-hit model in 
neural tissue as well as the rodent models currently available. Then I will 
introduce a new model of TSC using patient-derived, human-induced pluripotent 
stem cell (iPSC). Finally, I will provide evidence that these patient-derived iPSCs 
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have not undergone loss of heterozygosity, yet still display altered behavior 
consistent with changes in mTORC1 activity. These phenotypes of patient 
derived iPSCs include resistance to differentiation and increased cell survival. 
Together, these data suggest haploinsufficiency as an important mechanism for 
TSC pathogenesis. Chapter IV will explore how these data explain a multisystem 
disease, such as TSC, as a collection of various tissue-specific pathogenic 
mechanisms, and tie these findings to autism and epilepsy more broadly. 
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CHAPTER II 
CYSTOGENESIS AND ELONGATED PRIMARY CILIA IN TSC1-DEFICIENT 
DISTAL CONVOLUTED TUBULES 
This work was published in its entirety under the same title in the August 15, 
2012 issue of the American Journal of Physiology Renal Physiology (Armour, 
Carson, and Ess 2012). 
 
Introduction 
 
Tuberous Sclerosis Complex (TSC) is a multiorgan hamartomatous disease of 
the brain, skin, and kidney found in approximately 1 in 6,000 live births (Young 
and Povey 1998). Neurological symptoms of TSC predominate in young patients 
and include mental retardation, epilepsy, and autism (Crino, Nathanson, and 
Henske 2006). Renal pathology is less common in young children but is usually 
seen after the second decade of life. The renal pathology is diverse and includes 
cysts, angiomyolipomas (AML), and, in rare instances, renal cell carcinoma 
(O'Callaghan et al. 2004; Washecka and Hanna 1991). AMLs occur in up to 70% 
of patients with TSC and cysts are seen in ∼30% of patients (O'Callaghan et al. 
2004). While most kidney lesions are asymptomatic in TSC patients, a subset of 
patients present with severe polycystic kidney disease (PKD) that causes 
significant morbidity and mortality (Sampson et al. 1997). 
TSC results from a loss of function mutations of either the TSC1 or TSC2 
genes. In normal tissue, hamartin and tuberin (the protein products of TSC1 and 
TSC2, respectively) form a complex that regulates mammalian target of 
rapamycin (mTOR) signaling activity (Consortium 1993; Povey et al. 1994). The 
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mTOR kinase regulates many critical cellular processes, including control of cell 
size, proliferation, cell survival, and protein synthesis (Inoki, Corradetti, and Guan 
2005). mTOR carries out these functions with specific protein binding partners 
that associate into two distinct complexes. mTOR complex 1 (mTORC1) contains 
Raptor/mLST8/GβL, phosphorylates p70-S6 kinase 1 (S6K1) and eukaryotic 
initiation factor 4E-binding protein 1 (4E-BP1), and controls mRNA translation 
(Tee and Blenis 2005). mTOR complex 2 (mTORC2) contains Rictor/GβL/mSin1, 
directly phosphorylates and activates Akt and protein kinase Cα, and indirectly 
activates NDRG1 via SGK1 phosphorylation (Garcia-Martinez and Alessi 2008). 
In contrast to mTORC1, mTORC2 function is much less well defined but appears 
to be involved with cytoskeletal regulation (Sarbassov et al. 2004). Raptor and 
Rictor are mutually exclusive binding partners of mTOR, controlling substrate 
specificity as well as sensitivity to rapamycin, a selective mTORC1 inhibitor. 
Current data suggest that the hamartin/tuberin complex is a negative regulator of 
mTORC1 but a positive regulator of mTORC2 (Huang et al. 2009). Loss of either 
hamartin or tuberin then leads to increased mTORC1 activity but decreased 
mTORC2 activity (Huang et al. 2009; Wullschleger, Loewith, and Hall 2006). 
Current genetic models of TSC support a germline mutation inactivating one 
allele of either TSC1 or TSC2 for each patient. Loss of heterozygosity at the 
other allele allows constitutive activation of mTORC1 signaling, resulting in 
phosphorylation and activation of ribosomal S6K1 and other downstream targets 
and is thought to lead to hamartoma formation (Crino et al. 2010; Sepp, Yates, 
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and Green 1996). Contributions of decreased mTORC2 activity in TSC have not 
been well studied but may play an important role in TSC pathogenesis. 
Accumulating evidence connects mTOR signaling to kidney development 
and cystogenesis. Large deletions of both TSC2 and PKD1 in a subset of 
patients with TSC cause TSC and severe kidney disease. Intriguingly, recent 
reports show a direct physical interaction between tuberin and polycystin-1. This 
interaction is required for the proper subcellular localization of tuberin as well as 
mTORC1 inhibition (Dere et al. 2010; Shillingford et al. 2006). Additionally, 
hamartin has been shown to localize to the basal body of the primary cilia, an 
organelle the dysfunction of which leads to cystogenesis (Hartman et al. 2009). 
Furthermore, loss of either Tsc1 or Tsc2 in mouse embryonic fibroblasts and 
knockdown of tsc1a in zebrafish cause increased ciliary length (DiBella, Park, 
and Sun 2009; Hartman et al. 2009; Yuan et al. 2012). 
The first animal models of TSC were generated by conventional 
inactivation of the Tsc1 or Tsc2 genes and revealed an absolute requirement of 
either gene during embryonic development, as homozygous mutants died before 
embryonic day 10 (Kobayashi et al. 1999; Kwiatkowski et al. 2002). Rodents 
heterozygous for Tsc1 or Tsc2 develop kidney lesions in adulthood with some 
kidney lesions progressing to malignancy (Kwiatkowski et al. 2002; Kobayashi et 
al. 1999; Yuan et al. 2012). To define the role of hamartin in specific organs, 
conditional knockout (CKO) models of Tsc1 have been generated to dissect 
tissue-specific pathogenesis in TSC (Traykova-Brauch et al. 2008; Uhlmann et al. 
2002; Wang et al. 2007; Zhou, Brugarolas, and Parada 2009). Conditional loss of 
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Tsc1 in the proximal convoluted tubule (PCT) resulted in cystic kidneys, although 
the mechanisms linking dysregulation of mTORC1 and mTORC2 signaling with 
cystogenesis were not extensively studied (Zhou, Brugarolas, and Parada 2009). 
We now show that CKO of the Tsc1 gene in the distal convoluted tubule 
(DCT) causes cystogenesis. In these kidneys, there is both increased mTORC1 
and decreased mTORC2 signaling. Notably, primary cilia in the DCT are longer 
than those from control mice, suggesting defects in cilia structure and function. 
Treatment of these CKO mice with the mTORC1 inhibitor rapamycin prevented 
cystogenesis and normalized cilia length. However, loss of mTORC2 activity 
alone, through CKO of the Rictor gene in the DCT, did not cause cystogenesis or 
alter cilia length. Our findings suggest that loss of the Tsc1 gene in the DCT is 
sufficient for renal cystogenesis in TSC. This appears to require increased 
mTORC1 activity, possibly through cilia-dependent mechanisms that may be 
both cell-autonomous and non-cell-autonomous. 
 
Materials and Methods 
 
Mice: Emx1-Cre mice were obtained from Jackson Laboratories (Bar Harbor, 
Maine; line no. 005628) and maintained on a C57Bl/6 background. Mice with a 
Tsc1 “floxed” allele were obtained from Dr. D. Gutmann (Washington University, 
St. Louis, MO) and maintained on a mixed SV129J/C57Bl/6 background. Mice 
with the Rictor floxed allele were a gift of Dr. Mark Magnuson (Vanderbilt 
University) and were maintained on a C57Bl/6 background (Shiota et al. 2006). 
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Through interbreeding, we generated Tsc1Flox/Flox;Emx1-Cre mice (Tsc1 CKO) 
and RictorFlox/Flox;Emx1-Cre (Rictor CKO) mice that are homozygous for either the 
Tsc1 or Rictor floxed allele and heterozygous for Emx1-Cre. Heterozygous 
Tsc1Flox/wt;Emx1-Cre animals were used as controls and were indistinguishable 
from other control genotypes including Tsc1Flox/Flox or Tsc1Flox/wt Emx1-Cre 
negative mice. RictorFlox/Flox;Cre-negative animals were used as controls for 
Rictor CKO mice. Cre reporter strains included Z/EG transgenic mice (Jackson 
Laboratories; line no. 004178) and mTomato/mGFP transgenic mice (Jackson 
Laboratories; line no. 007676). Animal experiments were approved by the 
Vanderbilt Institutional Animal Care and Use Committee. 
 
Serum Chemistries: Blood samples were collected at euthanasia through cardiac 
puncture. Initial blood urea nitrogen (BUN) measurements were performed by the 
laboratory of Dr. Raymond Harris (Vanderbilt University). Additional BUN and 
serum chemistries performed by Antech (Southaven, MS). 
 
Rapamycin treatment: Rapamycin (LC Laboratories, Woburn, MA) was dissolved 
in a stock solution at 30 mg/ml in ethanol. Before use, the stock solution was 
diluted with vehicle 0.25% Tween 20/0.25% polyethylene glycol in PBS. Tsc1 
CKO mice and control littermates received intraperitoneal injections with either 
rapamycin (3 mg/kg) or vehicle twice a week, starting at postnatal days (P)13–15. 
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Antibodies: Arl13b (1:500; gift of T. Caspary, Emory University, Atlanta, GA), 
aquaporin 1 (AQP1; 1:500; Abcam), AQP2 (1:500; Abcam), calbindin D-28k 
(1:2,000; Swant), NCC (1:500; Millipore), fluorescein-labeled Lotus 
Tetragonolobus Lectin (1:2,000; Vector Laboratories), phospho-Akt Serine473 
(clone D9E, 1:1,000; Cell Signaling), phospho-S6 Serine235/236 (1:1,000; Cell 
Signaling), Akt (1:1,000; Cell Signaling), S6 ribosomal protein (clone 5G10, 
1:1,000; Cell Signaling), phospho-NDRG1 Thr346 (1:1,000; Cell Signaling), and 
actin (1:1,000; Cell Signaling). 
 
Immunofluorescence and imaging: Paraffin sections underwent antigen retrieval 
in 10 mM citrate buffer. Both frozen and paraffin sections were blocked in 5% 
normal goat serum, incubated in primary antibodies overnight at 4°C, followed by 
AlexaFluor conjugated secondary antibodies (Invitrogen) for 1 h. Slides were 
mounted with Vectashield (Vector Laboratories). Photomicrographs were taken 
using an Olympus BX UCB epifluorescence microscope and a Hamamatsu 
ORCA-ER CCD camera. Photomicrographs for cilia were taken on a Nikon 
spinning disk confocal microscope (Quorum Systems) with Metamorph software. 
Z-stack images were Z-projected, and cilia length was measured using ImageJ 
Software (Version 1.43S; National Institutes of Health). Cilia length was 
measured from calbindin-positive tubules in each photomicrograph using 
sections obtained from three control and three Tsc1 or Rictor CKO mice. 
Measurements of cilia length were done while blinded to genotypes or treatment 
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with vehicle or rapamycin. Due to the variability of numbers of visible cilia in each 
section, between 87 and 150 cilia were measured for each group. 
 
Immunoblotting: Kidneys were snap frozen in liquid nitrogen and homogenized in 
RIPA buffer containing phosphatase and protease inhibitor cocktails (Sigma-
Aldrich). Western blotting was completed using standard conditions. Blots were 
probed with either horseradish peroxidase-conjugated secondary antibodies (GE 
Healthcare) or with fluorescent-tagged secondary antibodies, Alexa 680 (rabbit; 
Invitrogen), and IRDye 800 fluorochromes (mouse and rat; Licor). For 
horseradish-peroxidase-conjugated secondary antibodies, signal was developed 
using ECL Western blotting substrate (Pierce, Rockford IL) and visualized on 
BioMax film (Kodak). Fluorescent-tagged secondary antibodies were visualized 
using an Odyssey fluorescence scanner. After visualization, digitized band 
densities were quantitated using ImageJ (National Institutes of Health). 
 
Results 
 
Loss of Tsc1 in the DCT increases kidney size 
 
Patients with TSC have multiorgan manifestations, usually with early neurological 
involvement followed by renal involvement in older children and adults. To 
address the dual pathologies of kidney and brain in TSC, we generated Tsc1 
CKO (Tsc1Flox/Flox;Emx1-Cre, CKO) mice. While usually described as a “brain-
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specific” gene, the Emx1 promoter also directs Cre expression in the kidney 
(Briata et al. 1996; Inoue et al. 2004). Tsc1 CKO mice are postnatally viable but 
small, with extensive brain abnormalities, seizures, and complete mortality by 
P25 (Carson et al. 2012). Because available antibodies are not suitable to 
determine hamartin levels, we assessed Tsc1 gene inactivation by isolating 
genomic DNA from kidneys and used PCR to determine recombination status. As 
expected, DNA from Tsc1 CKO kidneys yielded both recombined and 
unrecombined bands indicating targeted heterogeneity within the kidney, while 
control kidneys had only the unrecombined Tsc1 gene (data not shown). By P15, 
kidneys from Tsc1 CKO mice were larger than littermate controls (Figure 2.1A). 
When normalized for total body weight, the difference in kidney size was even 
more striking (Figure 2.1B). Despite size abnormalities in the Tsc1 CKO kidneys 
at P15, there was no significant change in blood urea nitrogen (BUN), a marker 
of kidney function, between Tsc1 CKO mice and littermate controls (Figure 2.1C). 
This suggests that Emx1-Cre-driven loss of Tsc1 in the kidney leads to kidney 
size abnormalities but not overt renal failure, suggesting the premature death of 
Tsc1 CKO mice is likely due to their extensive brain pathology (Carson et al. 
2012). 
 
Increased mTORC1 signaling and mild cystogenesis 
 
To determine if abnormalities of kidney size were associated with 
increased mTORC1 signaling, we measured levels of phospho-S6 in kidney 
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Figure 2.1 Postnatal day (P)15 Tsc1 conditional knockout (CKO) mice have large 
kidneys, renal cysts and increased mammalian target of rapamycin complex 1 
(mTORC1) signaling. A: kidney weights from control (solid line) or Tsc1 CKO mice 
(dashed line) at P6 to P15; n ≥ 3 for each group. *P < 0.03. B: kidney weight normalized 
to body weight from P15 control and Tsc1 CKO mice. (control n = 9; CKO n = 3). *P < 
0.03. C: no differences in blood urea nitrogen (BUN) levels from control and Tsc1 CKO 
mice. *P > 0.05, Student's t-test (control n = 13; CKO n = 6). D: immunoblotting for 
phospho-S6 reveals increased mTORC1 activity. Blots were stripped and reprobed for 
total S6 levels. E: immunoblotting for phospho-Akt (Ser473) reveals decreased mTORC2 
signaling. F: decreased phospho-NDRG1 (Thr346) further reveals decreased mTORC2 
signaling in P15 Tsc1 CKO kidney compared with littermate controls. Data were 
analyzed with Student's t-test. *P < 0.001 for phospho-S6, P < 0.05 for phospho-Akt and 
*P < 0.005 for phospho-NDRG1. All graphs are plotted as means ± SD, control extract 
expression levels were set to 100%. G and H: hematoxylin and eosin (H&E) staining of 
kidney sections from P15 control and Tsc1 CKO mice. Moderate cystic dilations are 
seen in kidneys from Tsc1 CKO mice. I and J: immunofluorescence for phospho-S6 in 
control and Tsc1 CKO mice. Phospho-S6 is diffusely expressed in the majority of the 
Tsc1 CKO kidney but found only in isolated cells in kidney from control littermates. Scale 
bars = 100 µm. 
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extracts from control and Tsc1 CKO kidneys. P15 CKO kidneys had increased 
ratios of phospho-S6 to total S6, indicating increased mTORC1 signaling (Figure 
2.1D). We also examined mTORC2 signaling using phosphorylation of Akt at 
Ser473, a sensitive and specific readout of mTORC2 activity (Jacinto et al. 2006; 
Shiota et al. 2006). We found a significant reduction of phospho-Akt in these 
same kidney samples (Figure 2.1E). Additional evidence for decreased 
mTORC2 signaling is seen by reduced phosphorylation of NDRG1 at Thr346 
(Figure 2.1F). Histological examination of kidneys from Tsc1 CKO mice at P15 
showed cystic changes when compared with littermate controls (Figure 2.1G,H). 
Immunofluorescence for phospho-S6 again showed increased mTORC1 
signaling throughout the kidney in Tsc1 CKO mice compared with (Figure 2.1I-J). 
Interestingly, both cystic and morphologically normal appearing tubules had 
increased mTORC1 signaling. 
 
Emx1-Cre expression in the DCT 
 
To determine expression within the kidney, we crossed Emx1-Cre mice to 
reporter animals that express GFP only after exposure to Cre recombinase. 
Animals transgenic for both Emx1-Cre and Z/EG revealed GFP signal within the 
cortex but not medulla. GFP coexpression was determined within the kidney 
using markers for the DCT (calbindin and NCC), the PCT (Aqp1), and collecting 
duct (Aqp2). Abundant GFP coexpression was seen with calbindin (Figure 2.2A-
C). and similar results were seen with NCC (data not shown). While most cells in 
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 Figure 2.2 Emx1-Cre mediates gene 
recombination in the distal convoluted tubule. 
A–C: GFP expression from Cre recombinase fate 
mapping (A) and calbindin (CALB), a marker of the 
distal convoluted tubules (DCT; B), colocalize in the 
cortex of the kidney, merged image (C). Neither 
AQP1, a marker of the proximal tubule, nor 
aquaporin 2 (AQP2), a marker of collecting ducts, 
colocalize in the cortex with GFP (D–F and G–I, 
respectively). Only faint reporter GFP was observed 
in the medulla, and this signal did not colocalize with 
AQP2 (J–L). Scale bar = 100 µm. 
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the DCT were double labeled with GFP, a few calbindin- and NCC-positive cells 
did not double label, suggesting that a subset of DCT cells did not express 
Emx1-Cre and were not targeted. GFP did not coexpress with either Aqp1 or 
Aqp2 in the kidney (Figure 2.2D-L), indicating that Emx1-Cre expression was 
restricted to the DCT. 
 
Rapamycin withdrawal from Tsc1 CKO mice leads to massive kidney 
enlargement and severe cystogenesis 
 
To see if kidney abnormalities in Tsc1 CKO mice were dependent on 
increased mTORC1 signaling, we treated Tsc1 CKO mice twice weekly with 
rapamycin starting at P14 and continuing until P90. Using this regimen, we 
achieved nearly 100% survival of CKO animals at P90, whereas prior natural 
history studies (Carson et al. 2012) demonstrated complete mortality by P25. A 
group of control and Tsc1 CKO animals were euthanized at P90 while on 
rapamycin, with another group of control and Tsc1 CKO animals euthanized on 
P120, 30 days after stopping rapamycin. On rapamycin, kidneys from P90 Tsc1 
CKO mice were slightly larger than kidneys from littermate controls (Figure 2.3A). 
However, in the post-rapamycin group, kidneys from Tsc1 CKO mice were 
greatly increased in size compared with control littermates (Figure 2.3A-B). 
While some small cysts were seen in P90 Tsc1 CKO kidneys on rapamycin 
(Figure 2.3C-D), P120 Tsc1 CKO mice post-rapamycin exhibited severely dilated 
cystic-appearing structures (Figure 2.3E-F). While Emx1-Cre expression 
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Figure 2.3 Rapamycin treatment partially inhibits cyst formation in Tsc1 
CKO mice and upon withdrawal causes giant cystic kidneys. Two groups of 
mice were treated with rapamycin from P15 to P90. At P90, kidneys from one 
group of animals euthanized on rapamycin were analyzed. For the second group 
of animals, rapamycin treatment was discontinued at P90 and mice were 
euthanized 30 days post rapamycin treatment at P120. A: Rapamycin treatment 
reduces cystogenesis in Tsc1 CKO kidneys. After rapamycin withdrawal Tsc1 
CKO kidneys become much larger than those from control littermates (n ≥ 3 for 
each group of control and Tsc1 CKO mice). B: gross images of representative 
Tsc1 CKO kidneys on rapamycin at P90 (left) or 30 days post rapamycin 
treatment at P120 (right). C–F: H&E staining of paraffin sections from Tsc1 CKO 
and control littermate kidneys on or off of rapamycin. Rapamycin-treated Tsc1 
CKO mice have slightly dilated tubules at P90 (D) compared with controls (C). At 
P120, 30 days post rapamycin treatment, kidneys from Tsc1 CKO show large 
cystic dilations of all tubules (F) compared with littermate controls (E). G–J: 
immunofluorescence for LTL [proximal convoluted tubule (PCT) marker, green] 
and the calbindin (DCT marker, red). Dilations of both the PCT and DCT are 
observed while on rapamycin (H) and post rapamycin treatment (J) compared 
with controls (G and I, respectively). Graphs are plotted with means ± SD. Data 
were analyzed with Student's t-test. *P < 0.001. Scale bar = 100 µm. 
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appeared to be restricted to the DCT (Figure 2.2), cystic dilatations were seen in 
Tsc1 CKO in both the PCT and DCT (Figure 2.3G-J), suggesting both cell-
autonomous and non-cell-autonomous mechanisms. 
To further explore mTORC1 and mTORC2 signaling in the kidney, Tsc1 
CKO and control mice were treated with rapamycin from P14 to P40. Kidneys 
were removed within 24 h of the last dose of rapamycin or 2 wk following 
rapamycin cessation. Immunoblots revealed increased mTORC1 signaling as 
indicated by pS6 levels in Tsc1 CKO kidneys 2 wk after rapamycin cessation, 
while levels in Tsc1 CKO and control kidneys on rapamycin were suppressed to 
levels below those seen in control mice off rapamycin (Figure 2.4). As the 
Tsc1/Tsc2 genes have been reported to activate mTORC2 signaling, we 
assessed Akt phosphorylation at Serine473. Using this same group of control 
and Tsc1 CKO mice, we found significantly decreased levels of mTORC2 
signaling in Tsc1 CKO mice that were on rapamycin as well those examined after 
rapamycin withdrawal (Figure 2.4). These overall results suggest that renal 
abnormalities in Tsc1 CKO mice are mainly due to mTORC1-dependent 
signaling. However, rapamycin treatment did not completely reverse the 
pathology, with P90 animals on rapamycin still displaying cystic changes, 
suggesting other mechanisms including decreased mTORC2 signaling may 
contribute. Alternatively, rapamycin treatment starting at P14 may simply be too 
late to reverse kidney pathology. Rapamycin injections at P6 were attempted but 
hampered by toxicity and mortality in both Tsc1 CKO and control animals. 
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Figure 2.4 Rapamycin treatment normalizes mTORC1 but not mTORC2 
signaling in Tsc1 CKO kidneys. Two groups of animals were treated with 
rapamycin from P15 to P40. Kidneys were taken from the first group of 
euthanized animals at P40 (n = 4 for control mice and n = 3 for CKO). 
Rapamycin treatment was discontinued in the second group of animals for 14 
days, from P40 to P54 and protein extracts made from these kidneys at P54 (n = 
3 for control and n = 2 for CKO). A: mTORC1 signaling, as shown by S6 protein 
phosphorylation, in Tsc1 CKO kidneys was decreased to that seen in control 
animals with rapamycin treatment. Post rapamycin phospho-S6 levels were 
greatly increased. *P < 0.05. B: mTORC2 signaling, as shown by Akt 
phosphorylation at Serine473, in P40 Tsc1 CKO kidneys was significantly 
decreased while on rapamycin. *P = 0.039. While trending towards significance, 
CKO extracts post rapamycin treatment did not have statistically significant 
decreases in phospho-Akt (Serine473); P = 0.12. 
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 Loss of Rictor in the DCT is not sufficient to cause overt kidney 
abnormalities 
 
These findings with rapamycin suggest that reversal of mTORC1 signaling 
was largely responsible for the kidney pathology in Tsc1 CKO mice. To isolate 
the contribution of decreased mTORC2 signaling during kidney development, we 
developed a Rictor CKO mouse model using the same breeding strategy used 
for Tsc1 CKO mice. These homozygous Rictor floxed mice with a single copy of 
Emx1-Cre (Rictor CKO) are viable with no overt brain abnormalities (R. P. 
Carson and K. Ess, unpublished data). At P15, kidneys from Rictor CKO mice 
also had no noticeable differences in weight compared with control littermates 
(Figure 2.5A-B). As antibodies against Rictor did not give reproducible results, 
mTORC2 signaling was assessed using levels of phospho-Akt (Serine473). No 
differences were seen in Rictor CKO compared with control mice (Figure 2.5C), 
likely due to decreased mTORC2 signaling being restricted to the DCT. To 
determine if the Rictor gene was inactivated, we extracted genomic DNA from 
kidneys and used PCR to measure recombination. DNA from Rictor CKO mice 
had unrecombined and prominent recombined bands, indicating Rictor 
inactivation in a subset of the kidney (Figure 2.5D). Kidney DNA extracted from a 
control littermate only showed the unrecombined gene. Rictor CKO kidneys 
appeared normal and indistinguishable from littermate controls (Figure 2.5E-F). 
Coimmunofluorescence for phosphorylated NDRG1, a downstream indicator of 
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Figure 2.5 Rictor CKO kidneys at P15 do not develop cysts. A and B: kidneys from 
P15 Rictor CKO mice did not show alterations in kidney weight nor in kidney-to-body 
weight ratios compared with control littermates (control n = 15; CKO n = 7). C: no 
changes in AKT phosphorylation at Serine 473 were detected through western blot 
analyses of protein extracts from P9-P15 Rictor CKO mice. D: PCR reveals 
recombination of exon three of the Rictor floxed allele in the kidney of Rictor CKO mice. 
E and F: H&E staining do not show any appreciable kidney abnormalities. G and H: 
immunofluorescence for pNDRG1, a marker of mTORC2 activity, and calbindin, a 
marker of the DCT, revealed undetectable levels of mTORC2 activity in the DCT in both 
control and CKO animals. 
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mTORC2 activity, and calbindin, a marker of the DCT, showed that even in 
kidneys from control animals the DCT has undetectable levels of endogenous 
mTORC2 activity (Figure 2.5G). Therefore, further decreases of mTORC2 
activity in the DCT of Rictor CKO animals were not measurable with 
immunofluorescence (Figure 2.5H). These findings suggest that kidney 
abnormalities seen after the loss of the Tsc1 gene in the DCT are largely due to 
increased mTORC1 signaling. 
 
Abnormalities of the primary cilia in the DCT from Tsc1 but not Rictor CKO 
mice 
The precise pathological mechanisms causing cystogenesis or brain 
malformations in TSC are poorly understood. As other diseases such as Bardet-
Biedl Syndrome and Joubert Syndrome also have shared brain and kidney 
pathology, we hypothesized that abnormalities of the primary cilia may connect 
TSC to “ciliopathies” (Badano et al. 2006). This hypothesis was bolstered by a 
recent report (Hartman et al. 2009) that hamartin is expressed in the basal body 
and Tsc1-deficient fibroblasts have abnormalities of cilia length. In addition, 
zebrafish with Morpholino knockdown of tsc1a also have elongated cilia and 
rapamycin treatment shortened cilia (Yuan et al. 2012). We measured the length 
of primary cilia in the DCT from P15 Tsc1 CKO and control mice and found 
longer primary cilia in the DCT from mutant mice (Figure 2.6B). In contrast, P90 
mice on rapamycin did not have changes in cilia length. However, the P120 Tsc1 
CKO mice (30 days after stopping rapamycin injections) again had increased cilia 
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 Figure 2.6 Primary cilia are longer in Tsc1-deficient but not Rictor-deficient 
tubules. A and B: representative photomicrographs of cilia in the DCT of Tsc1 
CKO mice on rapamycin at P90 (A) or 30 days after rapamycin withdrawal at 
P120 (B). Coimmunofluorescence for Arl13B (a marker of primary cilia) and 
calbindin (marker of the DCT). C: cilia length in untreated mice at P15, during 
rapamycin treatment at P90 and 30 days post rapamycin withdrawal at P120. 
Primary cilia in the DCT of kidneys from Tsc1 CKO mice were longer 30 days 
after rapamycin cessation. No changes in cilia length were noted between control 
mice and Rictor CKO mice. *P < 0.05. Scale bar = 25 µm. N.S, not statistically 
significant; n = 3 for each group of control, Tsc1 CKO and RictorEmx1−Cre CKO 
mice. 
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length compared with controls (Figure 2.6). To assess the potential contribution 
of decreased mTORC2 signaling to this phenotype, cilia from P15 Rictor CKO 
and control littermates were measured with no alterations in their length seen. 
Our pharmacologic and genetic data suggest that cilia length abnormalities in the 
DCT are due to increased mTORC1 but not decreased mTORC2 signaling. 
 
Discussion 
 
Our results demonstrate the formation of dilated cystic tubules from 
selective loss of Tsc1 in the DCT. This extends previous studies (Traykova-
Brauch et al. 2008; Zhou, Brugarolas, and Parada 2009) that have shown 
cystogenesis from Tsc1 inactivation in the PCT or from both the PCT and DCT. 
Additionally, we demonstrate an integral role for abnormal mTORC1 but not 
mTORC2 signaling in cystogenesis. This is shown by both pharmacological 
experiments using rapamycin and from the selective inactivation of the Rictor 
gene in the DCT. Furthermore, we found abnormally long primary cilia in Tsc1-
deficient but not Rictor-deficient DCT. The abnormal cilia length in the DCT of 
Tsc1 CKO mice is also reversible by treatment with rapamycin. These findings 
strongly suggest that increased mTORC1 but not decreased mTORC2 is the 
main contributor to cyst formation in TSC. Kidney disease initiation and 
progression in TSC may be due to defects in the structure or function of the 
primary cilia, linking TSC to other disorders that have dual kidney and brain 
pathologies. 
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Intriguingly, cystic changes were not restricted to the DCT. This is shown 
by increased mTORC1 activity at P15 throughout the kidney and cystic dilations 
within both the PCT and DCT in the kidneys at P120 post-rapamycin withdrawal 
(Figure 2.3). The presence of cysts in compartments other than Emx1-Cre 
expression domains suggests that non-cell-autonomous processes may be 
contributing to this cystic phenotype. This may also explain the decrease in 
mTORC2 signaling seen in Tsc1 CKO but not Rictor CKO kidney. Non-cell-
autonomous mechanisms have recently been reported in studies using human 
samples and from a zebrafish model of TSC (Crino et al. 2010; Kim et al. 2011). 
Newer therapies for patients with TSC need to consider potential non-cell-
autonomous mechanisms when designing therapies to alter the course of renal 
disease. An alternative explanation is that loss of the Tsc1 gene may cause 
altered cell fate, with DCT cells inappropriately expressing markers of the PCT. 
The primary cilium is an important mechanistic link between PKD and the 
mTOR pathway (Ibraghimov-Beskrovnaya and Natoli 2011). PKD is one of 
several disorders described as a “ciliopathy.” Links between cystogenesis and 
defects in primary cilium were first identified in a mouse model of PKD that has a 
mutation of Ift88, a gene required for normal primary cilia (Pazour et al. 2000). 
Other primary cilium-related proteins have been shown to also play a role in 
cystogenesis (Nauli et al. 2003; Zullo et al. 2010). Previously, longer cilia have 
also been found after kidney injury (Verghese et al. 2009). Here, our findings of 
altered cilia length after loss of Tsc1 in the DCT and normalization with 
rapamycin treatment link mTORC1 signaling to the primary cilia. Hamartin 
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expression at the basal body coupled with elongated primary cilia in Tsc1- or 
Tsc2-deficient mouse embryonic fibroblasts further supports our findings 
(Hartman et al. 2009). In addition to these results with cultured cells, the 
knockdown of tsc1a in zebrafish also increased cilia length and caused left-right 
patterning defects and cystic appearing kidneys (DiBella, Park, and Sun 2009; 
Yuan et al. 2012). The further use of complementary zebrafish and mouse 
models will greatly enhance our understanding of the role of the TSC genes and 
mTORC1 in the regulation of primary cilia length and function. Shortened cilia or 
loss of primary cilia has a clear functional consequence, including altered calcium 
flux and cell size control in response to flow. However, the functional impact of 
elongated primary cilia as we have seen here remains to be elucidated. Longer 
cilia may have disrupted flow-sensing capabilities through stiffening or other 
mechanical inhibition of cilia flexibility. Alternatively, longer cilia may disrupt 
normal retrograde and anterograde transport across the length of the cilia, 
preventing the normal activation and propagation of cilia dependent pathways 
such as Wnt signaling. Future experiments need to address the relative 
contributions of these mechanisms to cystogenesis. Insights into the functional 
impact of elongated cilia will be particularly useful in studying kidney phenotypes 
in animal models of TSC and understanding the pathogenesis of PKD and other 
kidney diseases that have altered mTORC1 signaling. 
47
 C+$37(5 III 
Heterozygous Patient Derived iPSC Lines Have Enhanced Cell Survival and 
Maintenance of Pluripotency 
 
Introduction 
As discussed in Chapter I, current models of TSC pathogenesis posit that 
while patients inherit one mutant copy of TSC1 or TSC2, it is only after a somatic 
mutation (resulting in loss of heterozygosity at either of these loci) that the 
pathologic lesions of TSC develop. Loss of heterozygosity leads to a clonal 
expansion and abnormal cellular differentiation resulting in a hamartoma. Data 
from both rodent models and TSC-associated human lesions support this two-hit 
model of hamartoma formation. Loss of heterozygosity at either TSC1 or TSC2 
has been well described in kidney, lung, and heart lesions from TSC patients 
(Sepp, Yates, and Green 1996; Henske et al. 1997; Cai et al. 2010; El-
Hashemite et al. 2003). In Chapter II, I presented evidence that this two-hit model 
of TSC progression is important in understanding the pathogenesis of kidney 
manifestations in TSC. 
For neurological pathologies, while rodent models have classically 
supported allelic loss of heterozygosity as a mechanism for TSC pathogenesis, 
evidence from human tissue has not. Therefore, the use of these rodent models 
as an appropriate model for human neuropathology has been called into question. 
In contrast to both non-neuronal lesions in patients and the various rodent 
models currently used, cortical tubers in patients rarely display loss of 
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heterozygosity. As cortical tubers are often epileptogenic foci in patients, 
neurological surgery and tuber excision is a treatment option for these patients. 
Tuber resections have provided many samples for DNA extraction and 
subsequent deep sequencing of these focal lesions. Surprisingly, attempts to 
identify acquired somatic mutations have revealed that second-hit mutations in 
cortical tubers are exceedingly rare (Henske et al. 1996; Niida et al. 2001; Qin et 
al. 2010). 
The rarity of detected second-hit mutations in surgically resected TSC 
patient brain tissue suggests an alternative mechanism to the two-hit hypothesis 
for the pathogenesis of cortical tubers. We hypothesize that human neuronal 
tissue is uniquely sensitive to alterations in hamartin and tuberin levels. 
Specifically, we propose that haploinsufficiency of either TSC1 or TSC2 results in 
minor mTOR signaling changes due to a dosage change in either hamartin or 
tuberin. In addition to the absence of detected second-hits, otherwise structurally 
normal tissue can still display metabolic abnormalities providing support for 
haploinsufficiency. These metabolic changes imply axonal dysfunction and 
demyelination in areas with only germline mutations in TSC1 or TSC2 (Wu et al. 
2013). These data further suggest that histologically normal brain tissue, without 
a loss of heterozygosity, may still behave abnormally at the molecular and 
cellular levels. 
The limitations of rodent models to accurately represent human 
neurological disease in TSC reveal the need for new ways to explore cortical 
pathogenesis in TSC. To address these challenges and to better define the role 
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of heterozygosity of TSC1 and TSC2 genes during the pathogenesis of TSC, we 
generated induced pluripotent stem cells (iPSC) from patients with TSC. These 
methods have provided the opportunity to directly study disease pathogenesis in 
human cells. Especially for neurological diseases, where human tissue is 
especially difficult to obtain, the generation of patient-derived iPSCs has allowed 
disease-specific neuronal tissue to be generated through directed differentiation 
of these cells. Additionally, iPSCs also provide a window to early events in 
embryonic development and cellular differentiation that may affect disease 
progression. 
 
Stem Cells and Pluripotency 
 
The derivation of embryonic stem cells (ESCs), first isolated from mice in 
1981, set a groundwork that allowed the understanding of pluripotency, self-
renewal, and differentiation pathways (Evans and Kaufman 1981). ESCs are self-
renewing cell populations derived from the inner cell mass of blastula-stage 
embryos, capable of differentiating into all cell types of the three primary germ 
layers. The derivation of human ESCs in 1998 allowed further understanding of 
fundamental stem cell pathways and the identification of species-specific 
differences in stem cell behavior (Thomson et al. 1998). ESCs revolutionized the 
study of embryogenesis, provided a source of human tissue to help understand 
normal function of organs derived from all three germ layers, allowed for rapid 
drug screening in human cells and sparked new hope regarding regenerative 
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medicine treatments. However, ethical concerns regarding the derivation and 
application of these cells have long provided obstacles for their laboratory use 
and governmental funding of these projects.  
Though cells normally progress from stem cells to terminally differentiated 
states during development, previous experiments using somatic cell nuclear 
transfer have demonstrated that this progression is not irreversible. Nuclei of 
differentiated cells retain the ability to generate new cloned animals and initiate 
normal developmental programs when introduced into enucleated oocytes 
(Gurdon 1962; Gurdon, Laskey, and Reeves 1975). The ability to “reprogram” 
these nuclei to an embryonic state in the presence of oocyte cytoplasm 
suggested that specific factors in the cytoplasm are responsible for this reversal 
of differentiation. 
Much work using ESCs has helped elucidate regulation of the two unique 
properties of stem cell populations: maintenance of pluripotency and self-renewal. 
These properties of ESCs are regulated by a complex network of genes. Three of 
the master regulators of this network are SOX2, OCT4, and NANOG. This 
regulatory network both promotes self-renewal and causes these cells to resist 
signaling cascades that induce differentiation. SOX2 and OCT4 cooperatively 
bind as a heterodimer to regulatory elements for many pluripotency related 
genes (Rodda et al. 2005). OCT4 (octamer-binding transcription factor 4) is a 
homeodomain transcription factor encoded by the gene POU5F1 (Takeda, Seino, 
and Bell 1992). It is maternally expressed in the oocyte and then is expressed in 
the embryo, continuing expression through the generation of the inner cell mass 
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(Scholer et al. 1990). SOX2 (sex determining region Y box 2) is a high motility 
group domain transcription factor, and is expressed in the developing inner cell 
mass (Yuan et al. 1995).  
OCT4 and SOX2 were identified as complementary transcription factors 
regulating pluripotency because loss of either OCT4 or SOX2 prevented normal 
embryogenesis (Avilion et al. 2003; Nichols et al. 1998). Conventional knockout 
of the Sox2 gene in mice causes embryonic lethality. In these knockouts, the 
epiblast does not develop and embryos die at implantation (Avilion et al. 2003). 
Oct4-null embryos progress slightly farther than Sox2-null embryos, but die 
shortly after implantation (Nichols et al. 1998). Furthermore, dosage effects of 
both genes regulate cell fate decisions of stem cell populations. Decreased Oct4 
results in differentiation to trophectoderm cells, while increased Oct4 promotes 
mesendodermal lineages (Chew et al. 2005; Niwa et al. 2005). Likewise, dosage 
effects of Sox2 relate to altered cell fates. Increased Sox2 promotes ectodermal 
and trophectoderm differentiation and prevents endoderm formation (Kopp, 
Ormsbee et al. 2008). Because both of these transcription factors are required 
for early embryogenesis and are able to control cell fate determination, much 
work has been done to understand the mechanisms by which these two 
important transcription factors influence stem cell behavior.  
Maintenance of pluripotency and self-renewal is also controlled through 
Nanog, a homeodomain transcription factor. Nanog is positively regulated by the 
binding of Oct4 and Sox2 to the Nanog enhancer region, and is required for 
pluripotency both in the epiblast as well as in vitro stem cell lines (Mitsui et al. 
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2003; Rodda et al. 2005). Like Oct4 and Sox2, loss of Nanog prevents epiblast 
formation (Mitsui et al. 2003). Initially, Nanog was identified in a screen of factors 
that could sustain pluripotency in media that promotes differentiation (Chambers 
et al. 2003). It was subsequently shown to be important for formation of the inner 
cell mass as well as the generation of stem cell lines from this population 
(Rossant and Tam 2009; Mitsui et al. 2003). While overexpression of Nanog 
inhibits differentiation, loss of Nanog causes a loss of pluripotency and 
differentiation to endodermal lineages (Mitsui et al. 2003; Chambers et al. 2003). 
Nanog can also bind the promoter regions for both Oct4 and Sox2, providing 
interesting feedback loops for these three master regulators (MacArthur et al. 
2012). 
The discoveries of master regulatory transcription factors in both mouse 
and human ESCs and the complicated networks they control to maintain 
pluripotency and self-renewal paved the way for the development of techniques 
for reprogramming differentiated somatic cells towards an embryonic state. This 
led to the generation of human induced pluripotent stem cells (hiPSC) through 
the introduction of master regulators and reprogramming of human fibroblasts 
(Takahashi et al. 2007). The first successful induction of pluripotency from 
somatic cells was completed with the exogenous addition of Oct4 and Sox2 
along with Klf4 and c-Myc (Takahashi and Yamanaka 2006). Introduction of 
these genes caused the cells to be gradually reprogrammed, eventually 
expressing other pluripotent markers like Nanog. These cells produced 
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teratomas and had the ability to generate cells from all three germ layers, similar 
to ESCs. 
During the reprogramming process, exogenous genes begin to remodel 
chromatin structure. Over 1,000 loci experience dramatic changes to 
chromosomal histone modification, most involving pluripotency-related genes 
(Koche et al. 2011). Following this remodeling, changes in gene expression at 
these loci are observed, including reactivation of genes involved in DNA 
replication and cell cycle progression (Mikkelsen et al. 2008). Reactivation of 
genes involved in early embryogenesis result in the morphology of cells reverting 
to more embryonic shapes as well as increased proliferation (Smith et al. 2010). 
Concurrently, fibroblast-specific genes begin to be silenced and these 
mesenchymal cells begin to behave as epithelial cells (Li et al. 2010). Finally, 
endogenous pluripotency genes like Oct4, Sox2, and Nanog begin to be 
expressed (Brambrink et al. 2008). The re-expression of these endogenous 
genes allows the reestablishment of pluripotency and self-renewal networks. 
Autoregulation of these pathways, through positive feedback loops, cause these 
cells to retain stem cell identity after exogenously introduced vectors are silenced 
(Kim, Chu et al. 2008; Jaenisch and Young 2008). 
 
Patient derived iPSCs as a model for TSC 
 
The generation of iPSCs is clearly useful in many fields of medicine and 
science. Patient specific iPSCs are especially promising for regenerative and 
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transplant medicine because they should minimize the risk of tissue rejection 
given their autologous nature (Wernig et al. 2008). We are currently utilizing 
iPSCs derived from both healthy and lesion TSC patient skin samples to model 
disease pathogenesis and discover underlying mechanisms of this disorder. We 
hypothesize haploinsufficiency of either TSC1 or TSC2 causes minor changes in 
mTOR signaling. This can prominently impact stem cell populations, as mTOR 
signaling is connected to many cellular processes crucial for normal stem cell 
function such as cell proliferation and survival.  
Increased mTOR complex 1 (mTORC1) activity signals for increased lipid 
biogenesis and increased translation, both necessary for cell proliferation 
(Laplante and Sabatini 2009; von Manteuffel et al. 1997). Increased mTORC1 
activity, therefore, provides new membranes for cell division and increases 
function of ribosomal machinery that is needed for cell growth prior to mitosis. 
Additionally, the two main downstream targets of mTORC1, S6K1 and 4E-BP1, 
are required for G1 phase progression. mTORC1 also increases cyclin D1 levels, 
promoting cell cycle progression (Fingar et al. 2004; Vadlakonda, Pasupuleti, and 
Pallu 2013). mTORC2 activity has long been connected to cell-survival pathways 
such as FOXO signaling and p53 through Akt activation (Birkenkamp and Coffer 
2003; Zhou et al. 2001; Sarbassov et al. 2005). However, mTORC1 activity has 
also been linked to cell survival, specifically after loss of cell-cell contact and 
anchorage depletion (Arakawa-Takeuchi et al. 2010). 
While connections between mTOR signaling and both proliferation and 
cell survival have been previously established, the relationship between mTOR 
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and pluripotency has only recently been explored. First, regulation of Nanog is 
controlled through the Akt signaling pathway, which is both upstream and 
downstream of mTOR activity (Niwa et al. 2009; Kim et al. 2010). Akt activation 
causes increased expression of Nanog that, in turn, through a positive feedback 
loop, increases expression of Sox2 and Oct4. 
 More recent work has revealed a more direct connection between 
mTORC1 signaling and the complex network controlling the generation of stem 
cell lines and the maintenance of pluripotency. Both increased and decreased 
mTORC1 activity affects generation of pluripotent stem cell lines. Hyperactivation 
of mTOR signaling in Tsc2-/- mouse embryonic fibroblasts (MEF) almost 
completely prevents reprogramming to iPSCs, while inhibition of mTORC1 
activity through rapamycin treatment can augment reprogramming efficiency in 
these cells (He et al. 2012). Conversely, greatly decreased mTOR activity also 
prevents maintenance of pluripotency. Conventional knockout of the mTOR gene 
prevents the expansion of embryonic stem cells (ESCs) from blastula-stage 
embryos to pluripotent self-renewing stem cell lines (Gangloff et al. 2004). 
Maintenance of pluripotency is also affected through altered mTORC1 activity. 
High doses of rapamycin push existing stem cells to differentiate to mesodermal 
and endodermal lineages (He et al. 2012; Zhou et al. 2009). Removal of 
knockout serum replacement (KOSR), a potent mTOR stimulator and a crucial 
component of stem cell maintenance media, also decreases maintenance of 
pluripotent cells (Zhou et al. 2009).  
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While extreme hyperactivation or hypoactivation of mTOR signaling can 
deplete stem cell populations or decrease somatic cells reprogramming efficiency, 
smaller changes to mTOR signaling can enhance maintenance of pluripotency. 
While high dose (10 nM) rapamycin treatment decreases reprogramming 
efficiency of somatic cells, low dose (0.3 nM) treatment may enhance 
reprogramming efficiency (Chen et al. 2011). Furthermore, Tsc2 siRNA 
knockdown and mTORC1 activation in existing murine stem cell lines prevent 
differentiation of the cells. This effect is phenocopied in knockdowns of Flcn and 
Fnip1/2, two putative downstream targets of mTORC1. Both Flcn and Fnip1/2 
appear to function by inhibiting the translocation of the transcription factor Tfe3 to 
the nucleus. This translocation is important in maintenance of pluripotency 
(Betschinger et al. 2013). In this model, increased mTORC1 activity inhibits Flcn 
and Fnip1/2 to allow Tfe3, a pluripotency-promoting transcription factor to 
translocate to the nucleus and activate gene expression.  
 Overall, these data suggest that mTORC1 activity is crucial to 
reprogramming, maintenance of pluripotency, and cell survival iPSCs. In this 
chapter we provide evidence that TSC patient-derived iPSCs heterozygous for 
TSC1 or TSC2 have alterations in mTORC1 controlled cellular functions. We first 
demonstrate the absence of loss of heterozygosity in our iPSC lines. We then 
show patient-derived iPSCs have increased survival when artificially stressed. 
Lastly, we provide evidence that these stem cells maintain pluripotency at higher 
rates than control iPSC lines. These data are consistent with moderately 
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increased mTORC1 activity, providing evidence that haploinsufficiency may be a 
mechanism for TSC pathogenesis. 
 
 
Materials and Methods 
 
Primary Fibroblast Cultures and iPSC Reprogramming:  
Primary fibroblasts from TSC patients (TSP12, 16, 20) and control 
volunteers (CA, CD, CE, and CF) were obtained by punch biopsy. The punch 
biopsy sample was cultured in DMEM (Gibco) supplemented with 10% fetal 
bovine serum (Sigma),10 units/mL penicillin and 10 ug/mL streptomycin. 
Fibroblasts from culture were then reprogrammed to iPS cells.  
Fibroblasts from TSP16, TSP20, CD, CE, and CF were reprogrammed 
using a plasmid transfection protocol as previously described (Okita et al. 2011). 
Briefly, 6.0 x 105 fibroblasts from each line were collected and suspended in 
130uL of electroporation buffer containing 1 ug/uL of each of three plasmid 
expression vectors. Combined the 3 vectors contain OCT4, SOX2, KLF4, L-MYC, 
LIN28, and shRNA to p53. Cells were electroporated using a Neon cell 
transfection system (Invitrogen). These cells were transferred to 10 mL DMEM 
(Gibco) supplemented with 10% FBS (Sigma) without antibiotics in 10 cm cell 
culture dishes (TPP). The following day, media was changed to DMEM (Gibco) 
supplemented with 10% fetal bovine serum (Sigma),10 units/mL penicillin and 10 
ug/mL streptomycin. After 7 days, cells were trypsinized and 1.0 x 105 cells were 
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replated on 10 cm gelatin-coated plates with 1.8x106 mitomycin C (Sigma) 
treated SNL cells. The following day media was changed to human embryonic 
stem cell media containing DMEM/F-12 with Glutamax (Gibco), Knockout Serum 
Replacement (Gibco), 1X non-essential amino acids (Sigma), 10 units/mL 
penicillin and 10 ug/mL streptomycin (MediaTech), 4 ng/mL bFGF (Promega) 
and 0.1 mM β-mercaptoethanol (Sigma). Media was replaced daily for 2 weeks. 
As iPS colonies appeared, colonies were isolated and plated onto Matrigel (BD 
Biosciences) coated plates in the human embryonic stem cell media as 
described above supplemented with LIF (Millipore) and ROCK Inhibitor (Y-
27632) (Millipore). iPSC lines were then expanded in mTESR1 media (StemCell 
Technologies) and used for further experiments.  
TSP12 fibroblasts were transduced with lentiviral vectors expressing KLF4, 
OCT4, and SOX2 (viPS Vector Kit, Open Biosystems), centrifuged at 800 x g for 
45 minutes at room temperature (Paya et al. 2006). CA fibroblasts were 
transduced with lentiviral vectors expressing mouse Slc7a1. Cells were then 
transfected with a mouse retrovirus to express human KLF4, OCT4, and SOX2. 
Six days later 36,000 fibroblasts were plated onto SNL feeder cells, in human 
embryonic stem cell media as described above. Colonies were picked after 2 
weeks and cell lines expanded as described above on Matrigel coated plates in 
mTESR1 media.  
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DNA Sequencing and TSC1/2 Mutation Identification: 
Genomic DNA for sequencing was isolated using DNeasy Blood and 
Tissue Extraction Kit (Qiagen). Exon-containing DNA was captured using 
SureSelect XT (Agilent). Next generation sequencing was done on an Illumina 
HiSeq2000 (Solexa) through the Vanderbilt Genome Sciences Resource. FASTQ 
files were processed by the Vanderbilt Genome Science Resource to variant call 
files. Putative causative mutations for TSC at the TSC1 and TSC2 loci were 
verified in the variant call files through identifying the same mutation in DNA 
samples from both fibroblasts and multiple iPSC lines from each patient. 
 
Single Cell Suspension Experiments: 
iPSCs from various cell lines were dissociated into a single-cell 
suspension by incubation at 37°C for 5 minutes in 0.5% Trypsin-EDTA (Gibco). 
Trypsin was diluted using mTESR1 media and cells were collected through 
centrifugation at 200 x g for 5 minutes. The supernatant was removed, and cells 
were washed in PBS and centrifuged again. iPSC were resuspended in mTESR1 
media, cells were counted and 50,000 cells were plated per well of a 24-well 
plate. Cells were allowed to grow for 12 hours for immunofluorescence 
experiments or 72 hours for alkaline phosphatase. Cells were treated with 20 nM 
rapamycin (LC Laboratories) dissolved in DMSO (Sigma). Vehicle treated cells 
were treated with DMSO only. 
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Alkaline Phosphatase Detection: 
 Cells were fixed using a citrate buffer/acetone solution. A Fast Violet B 
capsule (Sigma Aldrich) was dissolved in deionized water. The fast Violet B 
solution was applied to cells and incubated in the dark at room temperature for 
15 minutes. Fast Violet B solution was removed and cells were washed twice 
with distilled water. 
 
Immunohistochemistry: 
 Media was removed and cells were washed twice with warm PBS. Cells 
were fixed with ice-cold 100% methanol at -20°C for 10 minutes. Cells were 
washed in PBS and blocked in PBS with 5% Normal Goat Serum (Sigma) for 1 
hour. Cells were incubated with Nanog primary antibody in block (1:200, Cell 
Signaling) overnight at 4°C. Cells were washed three times and incubated in a 
secondary antibody Alexa Fluor-568 (1:500, Invitrogen) for 1 hour at room 
temperature. Photomicrographs were obtained using a Zeiss Axiovert 200M 
microscope and a Hamamatsu camera. Images as a group were adjusted for 
contrast and brightness and counted in ImageJ (NIH).  
 
Immunoblotting: 
iPSC lines were lysed in RIPA buffer containing protease and 
phosphatase inhibitors (Sigma) for 10 minutes on ice. Cellular debris was 
removed through centrifugation and cellular lysates were stored at -80°C. For 
nuclear and cytoplasmic fractionation, a NE-PER Nuclear Cytoplasmic Extraction 
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kit was used (Thermo Scientific). Standard techniques were used for 
immunoblotting and quantification. Blots were probed using primary antibodies 
overnight at 4°C. Primary antibodies used include hamartin (1:1000, Cell 
Signaling), Tuberin (1:1000, Cell Signaling), S6 (1:1000, Cell Signaling), 
phospho-S6 -Serine 240/244 (1:1000, Cell Signaling), Histone H3 (1:1000, Cell 
Signaling), β-actin (1:10,000) and Tfe3 (1:500 Sigma). Blots were incubated in 
secondary antibodies for 1 hour at room temperature. Secondary antibodies 
(1:10,000, Li-COR) were imaged using the Odyssey Imaging system and 
quantified with ImageJ (NIH).  
 
Statistical Analyses: 
Experiments were done in triplicate. Student’s t-test was used to 
determine significance, p-values as indicated in figure legends. Statistical 
analysis and graph generation were completed using Prism 5 software 
(GraphPad).  
 
Results 
 
Generation of Heterozygous iPSC Lines from TSC Patients 
 
We generated iPSCs from multiple patients (TSP12, 16, 20) in addition to 
healthy volunteers as controls (CA, CD, CE, CF). The pluripotency of cell lines 
derived from both TSC patients and controls were validated first through 
expression of various stem cell markers including alkaline phosphatase, OCT4, 
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and Nanog as shown through both quantitative PCR and immunofluorescence 
(Cawthon et al. 2013). The ability to differentiate to cells from all three primary 
germ layers was demonstrated through spontaneous differentiation of embryoid 
bodies from all stem cells lines and subsequent staining for cell types from all 
three germ layers. Finally, to ensure cellular stability of these lines, karyotypes 
obtained from all cell lines displayed no chromosomal abnormalities (Cawthon et 
al. 2013). 
DNA samples from 15 patients, from both iPSCs as well as primary 
fibroblast cultures from which the iPSCs were derived, were sequenced using 
highly redundant (>80X coverage for TSC1 and TSC2) exome sequencing to 
determine causative mutations in these patients and to identify any second-hit 
mutations. Single mutations were identified in eight of the 15 patients (Table 3.1). 
Consistent with previously described frequencies, of the eight detected mutations, 
only one patient had a mutation in TSC1, with the remaining 7 mutations located 
in TSC2. The location and nature of these mutations are described in Table 3.1. 
The majority of these mutations are frameshift or nonsense mutation. In no 
patients were two distinct mutations detected, suggesting that these cell lines are 
heterozygous for either TSC1 or TSC2. The absence of detected mutations in the 
remaining seven patient samples is likely due to limitations of the sequencing 
modality used, which is less likely to identify large insertion or deletions. To fully 
identify mutations in this patient population and further confirm the absence of 
second-hit mutations in these cell lines, other modes of mutation detection, such 
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Table 3.1 Identified mutations of TSC1 or TSC2 in 8 patients with TSC 
Patient Gene Chromosome 
Chromosome 
Location Mutation 
Type of 
Mutation 
TSP8 Tsc2 16 2131735 C to G Nonsense 
TSP20 Tsc2 16 2106206 T to A Nonsense 
TSP21 Tsc2 16 2113023 TTG to T Frameshift 
TSP22 Tsc1 9 135796754 G to A Nonsense 
TSP23 Tsc2 16 2129160 C to T Nonsense 
TSP24 Tsc2 16 2138045 CCA to C 
Deletion of 
Splice Site 
AG Acceptor 
TSP30 Tsc2 16 2121871 C to T Missense 
TSP31 Tsc2 16 2134478 C to T Nonsense 
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as multiplex ligation-dependent probe amplification should be used in future 
studies. 
Despite this limitation of our sequencing technique, immunoblotting for 
hamartin and tuberin gives further evidence for heterozygosity in these TSC 
patient-derived iPSCs. Most TSC1 mutations result in nonsense-mediated RNA 
decay, while most TSC2 mutations result from nonsense or frameshift mutations 
that result in a premature stop codon (Jeganathan et al. 2002; Maheshwar et al. 
1997). Therefore, if a loss of heterozygosity has occurred at either of these loci, 
we would expect to see an absence of hamartin or tuberin on western blot. 
Specifically to rule out the possibility of detecting a truncated N-terminal segment 
of tuberin lacking a functional GAP domain, we probed for tuberin using an 
antibody directed towards a C-terminal epitope. Immunoblot analysis revealed 
the presence of both hamartin and tuberin in our cell lines, consistent with a 
heterozygous nature of these cells (Figure 3.1A).  
Additionally, cells without either functional copy of either TSC1 or TSC2 
should display gross hyperactivation of the mTORC1 pathway. Instead, 
immunoblots for phospho-S6, a downstream readout of mTORC1 activity, show 
that patient-derived iPSCs have similar levels of mTORC1 activity as compared 
to controls (Figure 3.1 B). The combination of immunoblot analysis and deep 
sequencing data provides strong evidence that these TSC patient-derived iPSC 
are heterozygous for either the TSC1 or TSC2 loci. 
While these TSC patient-derived iPSCs appear to have normal mTORC1 
activity (as measured by pS6 levels with immunoblotting), patient-derived iPSCs 
65
!!!!!!
!!
Figure 3.1 TSC Patient Derived iPSCs express both TSC1 and TSC2 and do 
not have hyperactivation of mTORC1 activity. (A) Three patients derived iPS 
lines (TSP12-4, 16-11, and 20-7) have detectable tuberin and hamartin. (B) 
Patient lines (TSP16-11 and TSP20-7) do not have gross hyperactivation of 
mTORC1 as shown through S6 phosphorylation.  
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have phenotypes consistent with increased mTORC1 signaling, such as 
increased cell size and proliferation (Cawthon et al. 2013). In addition, treatment 
with the mTORC1 inhibitor rapamycin slows proliferation and decreases the cell 
size towards normal, further implicating more subtle changes in mTORC1 
signaling as underlying the phenotype of TSC patient-derived cells (Cawthon et 
al. 2013). 
 
 
TSC iPSC Have Increased Cell Survival and Maintenance of Pluripotency 
 
 We next wanted to explore whether heterozygous patient iPS lines 
demonstrated increased cell survival and resistance to differentiation. To test this 
hypothesis, we developed a technique to stress iPSC through single-cell 
dissociation and sparse plating. It is well established that, unlike murine cells, 
human stem cells do not grow well when dissociated into single-cell suspensions 
(Fong et al. 2004; Pyle, Lock, and Donovan 2006) Loss of cell-cell adhesions 
cause human ES cells to undergo apoptosis and spontaneously differentiate 
(Watanabe et al. 2007; Narumiya, Ishizaki, and Uehata 2000; Amit et al. 2000). 
Cells enzymatically dissociated, using trypsin or Accutase, are stressed at higher 
levels than mechanically separated cells and have plating efficiencies of less 
than 3% (Holm et al. 2013; Hasegawa et al. 2006). Therefore, to maximize cell 
plating and pluripotency after passaging, cells are often mechanically separated 
and allowed to remain in larger aggregations (Sjogren-Jansson et al. 2005; 
67
Rosler et al. 2004; Carpenter et al. 2004). In cases where cells are enzymatically 
dissociated, treatment with a Rho-associated coiled-coiled kinase (ROCK) 
inhibitor is required to prevent premature differentiation and apoptosis (Holm et al. 
2013; Watanabe et al. 2007). 
 To test the cell survival and maintenance of pluripotency of our TSC 
patient lines, we stressed the cells using enzymatic dissociation. Single-cell 
suspensions from multiple control and patient lines were prepared with 
trypsinization followed by resuspension in stem cell media, and were plated at 
50,000 cells/well of a 12-well dish. Cells were allowed to grow for three days, and 
a colorimetric substrate was used to detect alkaline phosphatase activity, which 
is a cell surface marker of pluripotent colonies (O'Connor et al. 2008). After cell 
dissociation and plating, TSC patient-derived cells expanded to fill the entire well, 
with the vast majority of these cells positive for alkaline phosphatase (Figure 3.2 
B). Conversely, control cell lines had much less densely plated cells with only a 
few colonies staining positive for alkaline phosphatase (Figure 3.2A). To test 
whether the increased survival and maintenance of pluripotency of TSC patient-
derived iPSC was mTORC1 dependent, we treated these single-cell suspensions 
with rapamycin (20 nM) 1 hour before and during plating. Rapamycin greatly 
reduced the number of alkaline phosphatase-positive cells (Figure 3.2C). 
 To determine whether this was simply a trypsin specific sensitivity, we 
completed the same experiment with a ‘gentler’ method of disassociating iPSCs, 
using Accutase to enzymatically dissociate the cells (Bajpai et al. 2008). The 
results were the same as seen previously with trypsin, with TSC patient-derived 
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Figure 3.2 TSC Patient Derived iPSCs have increased survival and 
maintenance of pluripotency 3 days after single cell suspension. Control (A) 
and patient lines (B) were enzymatically dissociated and plated at 50,000 cells 
per well of a 24-well plate. 3 days after plating, cells were stained for alkaline 
phosphatase activity. Density of the colorimetric assay were measured. 2 of the 3 
patient cell lines were significantly different than control lines (* p < 0.05). Density 
of all cell lines treated with rapamycin were significantly decreased compared to 
the same line treated with vehicle only († p < 0.05). 
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lines having increased survival and expression of pluripotency markers much 
more than controls (Data not shown). 
 To evaluate the possibility that differences in the doubling times of the cell 
lines accounted for some of the dramatic results seen 72 hours after plating, we 
dissociated and plated the cells through the same methods as before, but 
analyzed the cells 12 hours later. Of note, alkaline phosphatase is a cell surface 
marker and is digested through enzymatic dissociation techniques and does not 
recover within this 12 hour timeframe. Instead, to measure pluripotency at 12 
hours we used immunofluorescence for Nanog to determine the relative number 
of pluripotent cells. Patient-derived iPSCs had a dramatically increased 
percentage of Nanog-positive cells as compared to controls (Figure 3.3A-C). 
Additionally, a much larger number of patient-derived iPSCs survived single-cell 
suspension as compared to control lines (Figure 3.3D). 
After these results, we were interested in the mechanism of increased 
pluripotency of these cells. A recent paper using mouse ESCs showed that 
hyperactivation of mTOR signaling after Tsc2 knockdown resulted in the 
translocation of the transcription factor Tfe3 from the cytoplasm to the nucleus 
(Betschinger et al. 2013). This intracellular translocation is required for 
maintenance of pluripotency. However, knockdown of Tsc2 in this model resulted 
in detectable hyperactivation of mTORC1, which we have not been able to 
demonstrate in our iPSCs by immunoblotting (Figure 3.1). Preliminary analyses 
suggest increased TFE3 in the nuclear fractions of our patient cells compared to 
controls (Figure 3.4). While confirmatory experiments are required, this suggests 
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Figure 3.3 TSC Patient iPSCs have increased survival and maintenance of 
pluripotent markers 12 hours post single cell suspension and plating. Cell 
lines were enzymatically dissociated and plated at 50,000 cells per well of a 24-
well plate. (D) More patient cells adhered and survived than controls. (C) A larger 
percentage of cells retained staining of the marker of pluripotency Nanog as well. 
Representative images from controls (A, CD2) and TSC patient lines (B, TSP16-
11) are shown. * p < 0.05. 
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Figure 3.4 TFE3 is increased in the nucleus of TSC patient derived iPSCs 
A) Western blot of nuclear extracts from control and TSC patient derived iPSCs 
show increased nuclear TFE3 in patient lines. B) Relative levels of TFE3 on 
western blot, normalized to Histone H3 levels. 
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that increased TFE3 translocation to the nucleus may contributes to the 
increased pluripotency we have observed. Additionally, this suggests that subtle 
changes in mTOR signaling are sufficient for TFE3 translocation. 
 
Discussion 
 
These data, generated using patient-derived iPSCs, have provided novel 
insight into the mechanism of TSC pathogenesis and implicated pathways of cell 
survival and pluripotency. These patient lines are the first use of iPSCs to dissect 
the pathogenesis of TSC. TSC patient derived iPSCs are heterozygous for TSC1 
or TSC2 and are therefore a more accurate representation of the neuronal 
lesions seen in the disease. We propose that these phenotypes of patient-
derived iPSCs are due to haploinsufficiency of either TSC1 or TSC2. These data 
demonstrate human iPSCs may be an important tool in studying neurological 
manifestations of TSC, because other heterozygous models, including rodents, 
have minimal brain pathology.  
Interestingly, we have shown that these heterozygous cells have 
abnormalities consistent with altered mTORC1 activity, indicating that a loss of 
heterozygosity may not be necessary for disease phenotypes in the context of 
specific organ systems. Previously, we have shown these cells to be larger than 
and proliferate more quickly than controls, consistent with increased mTORC1 
activity. Furthermore, these deficits can be reversed through rapamycin 
treatment and inhibition of mTORC1 activity.  
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We have continued to build on these observations, and now have 
intriguing data that TSC patient derived iPSCs show increased survival and 
pluripotency. This increased survival may be due to an inhibition of apoptosis. 
Many cell types need cell-cell adhesions and proper anchorage to an 
extracellular matrix to survive. When these contacts are lost, cells go through cell 
cycle arrest and activate caspase-3 and other factors to induce apoptosis 
(Pelizon et al. 2002; Chiarugi and Giannoni 2008). The signal transduction 
between loss of anchorage and cell cycle arrest and apoptosis is mediated 
through ROCK1-dependant inhibition of mTORC1 signaling (Arakawa-Takeuchi 
et al. 2010; Park et al. 2011). Therefore, we suspect the increased survival in our 
single-cell suspension experiments is due to increased mTORC1 signaling. This 
is further supported through the reversal of this phenotype with mTORC1 
inhibition with rapamycin. To confirm this, activation of apoptotic signaling in 
dissociated cultures should be further examined in our TSC patient-derived 
iPSCs.  
These patient derived cells also maintained pluripotency more frequently 
than control cells. Our experiments indicate increased pluripotency may be due 
to increased levels of nuclear TFE3, though further work is needed to verify the 
mechanisms responsible for these phenotypes. The regulatory network 
connecting mTOR signaling to this translocation has recently been explored, but 
additional work needs to be done to determine whether putative mTOR targets 
involved in pluripotency such as Flcn1/2 and Fnip1 are truly substrates of 
mTORC1 (Betschinger et al. 2013). Additional studies are also needed to 
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determine whether these cells are resistant to directed differentiation towards 
specific cell types, such as toward neuronal fates. 
Overall, my data are consistent with the following model of TSC 
pathogenesis (Figure 3.5). Increases in mTORC1 signaling prevent transduction 
of pro-apoptotic and cell cycle arrest signals through ROCK1. Normally, cellular 
stress and anchorage depletion should cause ROCK1 to decrease mTORC1 
signaling through phosphorylation and activation of tuberin. Instead, in our TSC 
patient derived iPSCs, low levels of constitutively active mTORC1 blunt this 
response and instead promote cell survival. These same low levels of 
constitutively active mTORC1 permit the nuclear translocation of TFE3 to the 
nucleus via phosphorylation of FLCN1. Accumulation of TFE3 results in 
increased pluripotency of these cells. In keeping with this model, low dose 
rapamycin should reverse these phenotypes through inhibition of this subtle 
increase in mTORC1. 
The combination of increased survival and pluripotency, combined with 
previous data showing increased proliferation and cell size may be instructive to 
understanding the formation of cortical tubers. First, cortical tubers contain giant 
cells that may be mechanistically related to the cell size phenotype of these 
iPSCs. Increased proliferation and cell survival can easily manifest in solid 
organs as disorganized patterning. Without proper neurogenesis, focal lesions 
could form, comprised of improperly arranged cells. Additionally, increased 
pluripotency and cell survival could account for the abnormally differentiated and 
immature cells present in the cortical lesions. Progenitor populations may be 
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Figure 3.5 Proposed models of increased survival and pluripotency in TSC 
iPSCs. A) Patients lines have increased survival through blunted responses to 
ROCK1 signaling in response to single cell suspension techniques. B) Patient 
lines have slightly increased mTOR activity that promotes TFE3 translocation to 
the nucleus. 
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resisting normal differentiation cues in the context of subtle mTORC1 activation, 
thus remaining in a relatively undifferentiated state. This could account for the 
abnormal cells that display markers of both neurons and astrocytes. Future work 
will explore both the response of these iPSCs to differentiation cues and 
properties of differentiated neurons from these lines. These experiments will 
further define the pathogenesis of neuronal phenotypes of TSC. 
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 CHAPTER IV 
FUTURE DIRECTIONS: TISSUE SPECIFIC PHENOTYPES AND BROADER 
IMPLICATIONS FOR HUMAN HEALTH 
 
The work presented in this dissertation describes the characterization of 
TSC related phenotypes in both kidney and stem cell populations. In the kidney, 
we have shown that loss of Tsc1 and hyperactivation of mTORC1 signaling 
results in cystic kidneys, possibly through a ciliary related mechanism. In stem 
cell populations, I have identified that cell survival and maintenance of 
pluripotency are altered in cell lines heterozygous for TSC1 or TSC2. Here, I will 
discuss the relevance of the data presented. I have broken this chapter into three 
parts. In Part I, I will discuss why tissue specific pathogenesis occurs in TSC. 
Part II will discuss how understanding the mechanisms of pathogenesis in TSC 
provides a foothold to a better understanding of autism and epilepsy. In Part III, I 
will conclude with future directions of the experiments presented in Chapters II 
and III. 
 
Part I: Tissue Specificity of Pathogenesis 
  
One of the most important topics explored in TSC is how a germline 
heterozygous mutation contributes to focal, organ specific phenotypes. This is a 
pressing question in many diseases, whether it is other hamartomatous disorders 
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such as PTEN Hamartoma Tumor Syndrome or cancer syndromes such as 
retinoblastoma. My work in kidney and stem cell populations strongly suggests 
that separate mechanisms of disease pathogenesis can occur in different organ 
systems. Specifically in TSC, we observe loss of heterozygosity driving the 
pathogenesis of non-neuronal lesions, while neurologic phenotypes can occur 
with only heterozygous mutations of either TSC1 or TSC2. In TSC, tissue 
sensitivity to mutations in these genes is likely a combination of 1) differential 
levels of hamartin and tuberin in different tissue types, 2) the tissue specific 
functions controlled by mTOR signaling, and 3) expression of effector and 
modifier genes that can compensate for TSC1 or TSC2 disruption. 
The location and timing of hamartin and tuberin expression may provide 
clues to why only certain organ systems are affected in TSC. While hamartin and 
tuberin appear to be ubiquitously expressed, certain organs have higher levels of 
these proteins than others. Early in development hamartin and tuberin levels are 
high throughout the embryo, but levels are especially high and expressed very 
early in cardiac tissue. Other areas of high expression include the kidney and 
brain (Murthy et al. 2001). Organs with the highest levels of protein are likely the 
organs that would be most affected by a loss of these proteins. High expression 
in these organs embryonically, therefore, are not surprising, as these three 
organs have high rates of TSC associated pathologies. Furthermore, while levels 
of hamartin and tuberin decrease dramatically throughout the rest of the body 
postnatally, levels of these two proteins remain high, well into adulthood, in the 
brain. This suggests an important ongoing role in neurological tissue, which may 
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suggest higher sensitivity to subtle changes in the levels of these proteins.  
The distinct tissue specific cellular functions controlled through mTOR 
signaling may also play a role in determining which cell types are most sensitive 
to changes in hamartin and tuberin levels. Brain tissue dynamically regulates 
mTOR signaling to properly modulate many tightly regulated neuronal processes 
including axon growth, dendritic arborization, synaptogenesis, and protection of 
neurons from toxicity through regulation of autophagy (Jaworski et al. 2005; 
Kumar et al. 2005; Ravikumar et al. 2004; Miller and Kaplan 2003). These 
processes are controlled through an intricate signaling pathway and subtle 
perturbations can be magnified into large phenotypes. In the kidney, however, 
mTOR serves as a more blunt signal for cellular growth and provides a cellular 
mechanism to respond to injury and increased filtration demand in cases such as 
diabetic nephropathy or loss of contralateral kidney function (Nagai et al. 2005; 
Cleper 2012). This response is initiated primarily to increase organ mass to 
accommodate increased demand on the organ. This organ-wide response is in 
contrast to the fine alterations seen in neuronal tissue, such as synaptic changes 
in individual neurons. These differences of mTOR function in the brain and 
kidney may explain why brain tissue is sensitive to heterozygosity in TSC1 or 
TSC2, while kidney lesions require loss of both copies of either gene.  
Finally, effector genes or non-genetic environmental ‘second hits’ may be 
playing a role in the focal nature of lesions in the brain. Patients with TSC, while 
having similar causative mutations in TSC1 or TSC2 have wide ranging clinical 
severity. This is likely due to multiple confounding variables such as 
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environmental causes and mutations in modifier genes (Nadeau 2005). Perhaps 
other, yet unidentified, genes may be partially compensating for heterozygous 
loss of either of these genes in the brain, as is seen in other neurologic disease 
models (Tanabe, Martin, and Dauer 2012). Somatic mutations in progenitor cells 
may create a localized population of cells heterozygous for these yet unidentified 
compensatory genes. This may provide a specific region where the cells in TSC, 
already abnormal due to slight alterations in mTOR signaling, combined with 
altered compensation processes can initiate cortical tuber formation. Advances in 
sequencing should allow the comparison of genomic variation between skin and 
tuber samples from the same patients, allowing possible local modifier genes to 
be identified. We cannot rule out, however, the possibility that rare second hit 
mutations in TSC1 or TSC2 may generate organizing foci for tuber formation 
(Crino et al. 2010; Qin et al. 2010). As seen in our kidney model in Chapter II, 
loss of heterozygosity in the DCT can affect neighboring cells in the PCT. Non-
cell-autonomous effects of the rare giant cells with a somatic second hit, may still 
affect the location of tubers and severity of disease. While these cells appear to 
be electrically silent and may not be integrated into neuronal circuitry, they may 
be affecting neighboring cells through cell-cell contact or soluble factors (Cepeda, 
Andre, Flores-Hernandez et al. 2005; Cepeda, Andre, Vinters et al. 2005). 
Studies in kidney as well as the brain can help identify non-cell-autonomous 
mechanisms of altered mTOR signaling. iPSCs modified with knockdown of 
TSC1 and TSC2 grown in co-culture with cells heterozygous for the same gene 
could help tease out the role of non-cell-autonomous changes in TSC 
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pathogenesis. While the focal nature of hamartomas and the organs in which 
they occur are still poorly understood, the combination of iPSCs and rodent 
models should greatly enhance our knowledge of this phenomenon. iPSCs are 
an especially important tool as they are the first model that display readily 
apparent phenotypes in heterozygous cells. This tool will specifically help us 
understand the neurological signs of TSC, like cortical tubers, as well as 
neurological symptoms of TSC, such as autism and epilepsy. 
 
Part II: mTOR Signaling in Autism and Epilepsy 
 
Autism spectrum disorders are neurological diseases characterized by the 
three core behavioral abnormalities of impaired social interactions, 
communication deficits, and repetitive behaviors (Association 2000). Often these 
characteristic behaviors are present along with other comorbid conditions like 
epilepsy and cognitive disability, as is seen in TSC (Matson, Matson, and 
Beighley 2011). Autism is a growing problem, and current prevalence of the 
disease is estimated at 1% (Kogan et al. 2009). While much research has looked 
into the etiology of autism, no single cause has emerged. However, twin studies 
have suggested a largely genetic basis for the disease. Identical twins have up to 
a 90% concordance rate for the disorder (Bailey et al. 1995; Ronald and 
Hoekstra 2011). While many genes contribute to the pathogenesis of autism, 
TSC and other genetic syndromes have proved very useful tools in 
understanding this condition. Syndromes causing ASD with a single genetic 
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cause are specifically useful, because identification of mutated genes and their 
associated pathways provides a foothold to understand the etiology of the larger 
collection of disorders. While only 10% of all ASD patients have such 
neurodevelopmental syndromes, research into their associated pathologies has 
proven invaluable to understanding ASD as a whole (Hampson, Gholizadeh, and 
Pacey 2012). TSC related behaviors of autism including impaired social 
interactions, stereotypical behaviors and communication deficits were identified 
early in the 20th century, long before autism was described as a diagnosis 
(Critchley and Earl 1932; Kanner 1968). TSC remains one of the best-understood 
monogenetic causes of autism to date. In addition to TSC, Rett Syndrome, 
Fragile X syndrome, and PTEN hamartoma tumor syndrome are all single gene 
genetic disorders that cause autism. TSC and dysregulated mTOR signaling 
have been linked to autism, but recent work on these other monogenetic causes 
of autism has begun to reveal mTOR as signaling hub for ASD. Therefore 
understanding upstream control and downstream signaling mechanisms of 
mTOR may be crucial in identifying targets for autism treatments in the future. 
 Rett syndrome is a developmental disorder caused by mutations in the 
Methyl-CpG-binding protein 2 (MECP2) gene. This gene is found on the X 
chromosome. Males with mutations are thought to have embryonic lethal 
phenotypes and is thus only found in females. Patients with Rett syndrome 
develop normally until around 6 to 18 months of age. At onset, there is a 
developmental regression, specifically in motor development. Hand wringing 
behaviors become especially prominent (Davis 2011). Children with Rett 
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syndrome have severe neurological deficits including autism, epilepsy, and 
cognitive impairment (Chahrour and Zoghbi 2007). The MECP2 gene is a 
transcriptional regulator that works as through modifying chromatin structure 
(Nan et al. 1998). Rodent models have shown that Mecp2 regulates dendrite and 
spine morphogenesis as well as altering synaptic plasticity (Boggio et al. 2010; 
Kishi and Macklis 2005). Interestingly, these changes in neuronal function seem 
to be mediated through mTOR signaling. Rodent models with a loss of Mecp2 
show markedly decreased mTOR signaling, and levels continue to decrease as 
the disease progresses (Ricciardi et al. 2011). Furthermore, the loss of Mecp2 
and associated decrease in mTOR signaling results in decreased protein 
synthesis in these neurons (Ricciardi et al. 2011). Changes in protein translation 
have been clearly linked to altered synaptic activity and neuronal morphology, so 
it is likely decreased mTOR signaling and associated decrease in mTORC1-
dependant translation is responsible for these effects (Jaworski and Sheng 2006; 
Hoeffer and Klann 2010). Decreased mTOR activity in Rett Syndrome is 
particularly interesting, because it is the opposite direction of change as 
observed in TSC. This suggests that precise regulation of mTOR is crucial for 
normal neuronal function, and either activation or inhibition of the pathway may 
be detrimental to developmental disorders. 
 Fragile X syndrome (FXS) is another neurodevelopmental disorder 
characterized by cognitive impairment and autism, as well as macrocephaly. This 
disorder is a trinucleotide repeat disorder, where expansion of a trinucleotide 
causes silencing of FMR1 gene (Verkerk et al. 1991). Loss of FMR1 expression 
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causes increased protein synthesis, possibly through increased activation of 
metabolic glutamate receptor 5 (mGluR5) (Bear, Huber, and Warren 2004). 
Treatment with mGluR5 antagonists has shown some promise in reversing 
increased protein synthesis and FXS associated phenotypes (Krueger and Bear 
2011). Interesting, loss of FMR1 seems to increase synthesis of mTOR signaling 
components. Additionally, mGluR5 activation may be signaling directly through 
mTOR pathways to increase protein synthesis. Loss of FMR1 causes increased 
production of the catalytic subunit of PI3K, and subsequent hyperactivation of 
this kinase, an upstream regulator of mTOR signaling (Gross et al. 2010). Further 
experiments have shown that loss of FMR1 also increased assembly of mTOR 
Complex 1 and increased activity through S6 and 4E-BP1 phosphorylation 
(Sharma et al. 2010). This provides further genetic evidence that dysregulation of 
mTOR signaling may underlie some of the phenotypes in ASD. 
 PTEN hamartoma tumor syndrome is an autosomal dominant disorder 
caused by mutations in the phosphatase and tensin homolog (PTEN) gene and is 
characterized by hamartomatous growths in various organs including the skin, 
breasts and GI tract. While most of these lesions are benign, some will progress 
to malignancy. Patients with PTEN hamartoma tumor syndrome have 
approximately a 90% probability of cancer during their lifetime, most commonly of 
breast tissue (Riegert-Johnson et al. 2010). This syndrome encompasses many 
distinct sub-syndromes such as Cowden syndrome, Lhermitte-Duclos disease, 
and Proteus syndrome with similar causative mutations, but not completely 
overlapping pathologies (Salmena, Carracedo, and Pandolfi 2008). The protein 
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product of the causative gene, PTEN, is a negative regulator of the mTOR 
signaling pathway. Loss of PTEN results in the hyperactivation of mTOR 
signaling and formation of the characteristic hamartomas similar to TSC (Kwon et 
al. 2006). Finally, mouse models have shown that loss of Pten results in 
macrocephaly and autistic behaviors subsequent to this hyperactivation of mTOR 
signaling (Page et al. 2009). 
 In addition to TSC, it is interesting that this collection of the four most 
common monogenetic causes of autism all have disruption of mTOR signaling as 
a common component in disease pathogenesis. Understanding the regulation of 
this pathway and its downstream targets will be crucial to provide a foothold into 
the causative mechanisms of the varied causes of autism. In addition to these 
monogenetic causes, there is some clinical evidence that mTOR signaling may 
also be implicated in sporadic autism. Up to 30% of ASD patients have 
macrocephaly (Lainhart et al. 2006). This is similar to macrocephaly seen in TSC 
rodent models as well as patients with either PTEN hamartoma tumor syndrome 
or Fragile X syndrome. These macrocephaly inducing disorders all have 
identified increases in mTOR activity, and alterations of protein synthesis, cell 
growth, differentiation, and cell survival. Dysregulation of any of these cellular 
processes could manifest as increased brain volume. The high prevalence of 
macrocephaly in non-syndromic forms of ASD provides further support 
alterations in the mTOR signaling pathway in the pathogenesis of autism. 
 With these data implicating dysregulated mTOR as important in the 
pathogenesis of autism, pharmacologic modifiers of the mTOR signaling pathway 
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have begun to be explored as a therapeutic approach for autism. As the role of 
mTOR signaling is most closely related to TSC pathologies, initial studies have 
focused on treating TSC rodent models, as well as patients, with mTORC1 
inhibitors such as rapamycin. In mouse models, autistic-like behaviors in mice 
heterozygous for Tsc2 are reversed through mTOR inhibition (Sato et al. 2012). 
These promising results have spurred clinical trials in TSC patients, currently 
ongoing, exploring whether similar inhibitors can reverse autistic behaviors in 
humans (Sahin 2011). 
 While inhibition of mTOR signaling may be therapeutic in TSC, other 
autistic disorders may need a more targeted approach for therapy. For example, 
while Fragile X syndrome has increased mTOR signaling similar to TSC, this 
increased activity has the opposite downstream effects in the pathogenesis of 
each disease. Fragile X Syndrome shows activation of mTOR signaling 
downstream of mGluR5 activation (Sharma et al. 2010). This causes increased 
protein synthesis at the synapse and increased synaptic plasticity (Sharma et al. 
2010; Huber et al. 2002). Conversely, while protein synthesis is also increased in 
TSC, rodent models of TSC have impaired synaptic plasticity (von der Brelie et al. 
2006). In TSC, while cellular wide protein synthesis is increased, it appears that 
protein synthesis is, in fact, reduced in the synaptic compartment of these 
neurons (Auerbach, Osterweil, and Bear 2011). Therefore, while these two 
monogenetic disorders both have increased mTOR signaling, this dysregulation 
has opposite effects on synaptic plasticity. Surprisingly, double mutants 
heterozygous for both Tsc2 and Fmr1 do not display synaptic phenotypes in 
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contrast to each mutation alone. Presumably, the opposite effects on synaptic 
plasticity correct each other, resulting in properly functioning neurons (Auerbach, 
Osterweil, and Bear 2011).  
Understanding intricacies of mTOR signaling and disease specific 
differences should lead to insights in pharmacological targets. In Fragile X 
syndrome, specific inhibition of the mTOR pathway through targeting of mGluR5, 
upstream of the pathway, has been promising in rodent models of the disease 
(Krueger and Bear 2011; Vinueza Veloz et al. 2012). Downstream targets of 
mTOR signaling have also been modified to correct phenotypes in rodent models 
of autism. Downstream of mTORC1, the target of 4E-BP1, eukaryotic initiation 
factor 4E (eIF4E) has been linked to autism as well (Neves-Pereira et al. 2009). 
Fragile X syndrome, through increased mTORC1 and inhibition of 4E-BP1, has 
increased activation of eIF4E (Wang, Kim, and Zhuo 2010). The synaptic 
dysfunction in models of Fragile X syndrome is phenocopied when eIF4E is 
either overexpressed or disinhibited through the removal of binding partners 
(Gkogkas et al. 2013). Furthermore, pharmacological inhibition of eIF4E corrects 
the autistic behaviors seen in these mice (Gkogkas et al. 2013). The effective 
modulation of both upstream effectors, such as mGluR5, and downstream 
targets of mTOR signaling, such as eIF4E, to treat mouse models of ASD 
suggest that further understanding of the mTOR pathway should prove 
instructive for drug development. Elucidating the differential effects of altered 
mTOR signaling on various downstream targets such as synaptic protein 
synthesis and synaptic plasticity is important for identifying viable treatment 
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options for the many separate etiologies of ASD. 
 Our results in TSC patient derived iPSCs will augment the identification of 
these potential treatment targets for ASD. Patient derived iPSCs have increased 
cell size, proliferation, maintenance of pluripotency and cell survival, providing 
interesting clues to targetable downstream pathways for the treatment of TSC. 
As mentioned previously, macrocephaly is found in many of the monogenetic 
disorders causing autism as well as sporadic ASD cases. Our findings in human 
iPSCs help provide a basis for understanding this phenotype. Increased numbers 
of cells in the brain due to increased proliferation and survival, and the 
subsequent larger size of terminally differentiated cells can clearly result in a 
large brain phenotype. Additionally, we have shown increased pluripotency and 
cell survival in our TSC iPSC lines. Persistence of a progenitor pool, due to 
resistance to differentiation, will result in a longer period of neurogenesis and 
subsequently more cells in the brain. Further, proper neurodevelopment is 
dependant on an extensive period of pruning, with loss of synaptic connections 
as well as a large number of neurons. Increased survival of our iPSC lines 
suggest that this normal pruning process may be disrupted in TSC and result in 
more cells and inappropriate connections between cells. These mechanisms may 
also be seen in other monogenetic forms of autism that have altered mTOR 
signaling, as well as less well understood sporadic cases. Identification of 
pharmacological targets in the pathways of pluripotency (TFE3) or cell survival 
(ROCK) may be helpful in the treatment of TSC as well as other autism spectrum 
disorders. 
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Another important neurological symptom of TSC is epilepsy. Like autism, 
better understanding the mechanisms of epileptogenesis in TSC may provide 
clues to the cause and pathogenesis of epilepsy generally, as well as help 
identify targets for new antiepileptic drugs. Epilepsy is present in up to 90% of 
patients with TSC (Yates et al. 2011; McClintock 2002). Outside of TSC patients, 
epilepsy is still a relatively common disorder, affecting approximately 1% of the 
general population (Russ, Larson, and Halfon 2012). While current treatments for 
epilepsy focus on reducing excitatory circuits and enhancing inhibitory circuits in 
the brain, there is a paucity of treatments that target the molecular mechanisms 
underlying this disorder. mTOR signaling has been implicated in epileptogenesis 
and mTOR inhibitors have shown promise in treating the disease. Therefore, 
understanding of TSC may provide insight into how dysregulated mTOR 
signaling results in epilepsy. 
The process of epileptogenesis begins with some injury to neurological 
tissue. In the case of TSC, this injury is due to genetic and molecular causes. In 
many other cases, while genetic predisposition is likely important, the injury might 
be due to a traumatic or infectious insult to the tissue. Whatever the initiating 
insult, a silent phase of molecular changes eventually results in the presentation 
of multiple spontaneous seizures (Pitkanen and Lukasiuk 2011). During the silent 
phase, molecular changes result in neurogenesis, astrocytosis, and synaptic 
modifications (Pitkanen and Lukasiuk 2009). As mentioned earlier, current 
antiepileptic drugs can change the excitatory and inhibitory electrical pathways in 
the brain, managing the recurrence of seizures. These drugs, however are 
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largely ineffective at delaying or preventing the generation of seizures after an 
initial insult (Temkin 2009). Understanding the molecular changes during this 
silent phase will be instructive to identifying drugs that can inhibit the generation 
of epilepsy rather than just treatment of symptoms. As the cortical tubers in TSC 
display astrocytosis and alterations in neurogenesis, similar to acquired epilepsy, 
it is likely that understanding the pathogenesis of TSC will provide insight to 
epilepsy as a whole. Furthermore, as described earlier, mTOR signaling plays a 
major role in synapse formation and function. Alteration in synapses and the 
electrical circuitry is crucial in epileptogenesis (Dudek and Shao 2004). 
Additionally, mTOR is a major regulator of axon and dendritic growth and 
neuronal survival, both processes with roles in epilepsy (Kumar et al. 2005). 
These observations suggest mTOR signaling may mediate some of these 
changes during the silent phase of epileptogenesis. Interestingly, the ketogenic 
diet has been used for more than a decade in the treatment of epilepsy. While 
difficult for many patients to adhere to, this diet can be effective at controlling 
refractory epilepsy (Freeman, Kossoff, and Hartman 2007). Recently it has been 
shown this high fat, low carbohydrate diet limits circulating glucose, which in turn 
decreases mTOR activity (McDaniel et al. 2011). Decreased mTOR activity may 
be mediating the antiepileptogenic effect of this diet, further linking mTOR activity 
to epilepsy. Therefore, better understanding of the upstream control and 
downstream targets of mTOR signaling through models of TSC may lead to new 
treatments for epilepsy.  
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Increased mTORC1 signaling in TSC patients and the increased 
sensitivity of rodent models to seizures, linked mTOR dysregulation to clinical 
epilepsy. This prompted mTOR inhibitors, such as rapamycin to be tested as a 
possible treatment to prevent epileptogenesis, first in rodent models and then in 
human patients. In both cases, mTORC1 inhibitors were able to decrease 
seizure generation (Meikle et al. 2008; Muncy, Butler, and Koenig 2009). 
Additionally, in the mouse models, rapamycin treatment prevented the cellular 
changes associated with epileptogenesis including changes in synaptogenesis, 
cell survival, and astrocytosis (Meikle et al. 2008; Ehninger et al. 2008; Zeng et al. 
2008). Furthermore, during epileptogenesis, abnormal mTOR activity may cause 
detrimental changes to preventative inhibitory circuitry in the brain, and inhibition 
of mTOR may preserve these inhibitory circuits (Fu et al. 2012; Buckmaster and 
Wen 2011). Similar prevention of epileptogenesis and associated molecular and 
cellular changes with rapamycin treatment has been shown in numerous mouse 
models (Sunnen et al. 2011; Huang et al. 2010; Anderl et al. 2011). 
While these findings suggest mTOR signaling is important in the 
pathogenesis of epilepsy, the upstream signals from injury promoting mTORC1 
activity and the substrates of this complex that mechanistically mediate 
progression of the disorder remains to be determined. The findings presented in 
Chapters II and III may provide insight into the mechanisms that underlie 
epileptogenesis. Synaptic plasticity and function have been shown to be 
important mediators of epileptogenesis. Subtle changes in mTOR signaling and 
downstream protein synthesis can effect synapse function and perhaps lead to 
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the hyperexcitable state seen in epilepsy. Changes in cell survival and resistance 
to differentiation could also bias the brain towards seizure activity. If there are 
neuronal subtype specific sensitivities to altered mTOR activity, the relative 
balance between excitatory and inhibitory circuitry could be shifted, resulting in a 
hyperexcitable state. Soluble factors can also affect surrounding cells, 
contributing to epileptogenesis. These soluble factors can cause astrocytosis and 
the influx of immune cells (Vezzani et al. 2011). Insights into the non-cell-
autonomous mechanisms in TSC as demonstrated in the kidney may provide 
insight into how altered mTOR signaling can contribute to these pathogenic 
mechanisms in the brain. Furthermore, proper function of excitatory synapses is 
partially regulated by primary cilia, so ciliary changes in the brain may also alter 
these circuits (Kumamoto et al. 2012). Use of patient derived iPSCs should 
further the understanding of these epileptogenic mechanism to more broadly 
understand acquired epileptic disorders. Indentifying these mechanistic links 
between mTOR activity and epileptogenesis is a crucial step to development of 
eventual therapeutics. 
 
Part III: Future Directions 
 
Kidney Manifestations and Primary Cilia 
 
The work described in Chapter II showed that dysregulated mTORC1, but 
not mTORC2 causes cystogenesis in the kidney, possibly through dysregulation 
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of the primary cilia. Furthermore, loss of Tsc1 in the distal convoluted tubule has 
both cell-autonomous and non-cell-autonomous effects in cystogenesis. This 
work suggests future directions to establish functional changes in elongated 
primary cilia, explore primary cilia defects in other organ systems, and to 
determine the mechanism of non-cell-autonomous changes due to altered mTOR 
signaling. 
Elongated primary cilia provide an interesting mechanistic link between 
mTOR signaling and TSC kidney pathologies. As discussed in Chapter II, links 
between cystogenesis and defects in primary cilium have long been identified 
(Pazour et al. 2000; Nauli et al. 2003; Zullo et al. 2010). In the renal tubule, cilia 
protrude into the lumen in order to sense fluid flow (Pazour et al. 2002). Fluid 
flow in the tubule results in bending of the primary cilia, which in turn activates 
calcium channels and increases intracellular calcium levels (Praetorius and 
Spring 2001; Nauli et al. 2003). Changes in intracellular calcium in response to 
flow are thought to regulate cell proliferation and the plane of cell division (Luyten 
et al. 2010). Bending of the primary cilia also alters Wnt signaling, an important 
mediator of planar cell polarity (Sugiyama et al. 2011; Corbit et al. 2008). When 
ciliary structure or function is altered, dysregulated proliferation and plane of cell 
division, secondary to changes in calcium influx and Wnt signaling, results in 
cystogenesis. While shorter primary cilia have clear defects in transduction of 
signals detecting flow, it remains to be seen whether elongated primary cilia 
display similar deficits. 
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Future work should address the functional consequences of elongated 
primary cilia in the kidney tubules. Experiments should address whether Tsc1 
deficient cells have abnormal responses to flow, including changes in calcium 
influx, Wnt signaling, and planar cell polarity. Additionally while TSC related 
changes in cilia are due to mTORC1 activation as my work has shown, it remains 
to be seen if inhibition of mTORC1 can alter ciliary flow-sensing functions. 
Furthermore, it should be addressed whether non-mTOR related changes to cilia 
length could help correct the kidney phenotypes in these TSC models. Alteration 
of cilia stabilizing proteins such as DCDC2 to shorten elongated cilia and return 
them to normal lengths or pharmacological elongation of cilia in control animals 
with lithium may provide support for this model (Miyoshi et al. 2009; Massinen et 
al. 2011). Approaches using both genetic and pharmacological methods will 
provide evidence whether cystic phenotypes seen in TSC are due to structural 
constraints of longer cilia, or more subtle changes in ciliary signal transduction. 
Demonstrating changes in these processes will be crucial to understanding the 
mechanistic link between mTOR signaling and kidney pathology. 
The identification of altered primary cilia in TSC may provide insight into 
other tissue specific phenotypes of the disease. Ciliopathies, such as Bardet-
Biedl Syndrome, Meckel Syndrome, Joubert Syndrome and Oral-Facial-Digital 
Syndrome, are all caused by ciliary dysfunction and have dual brain and kidney 
involvement, similar to TSC (Quinlan, Tobin, and Beales 2008). The multi-system 
involvement and prominent effects in the brain and kidney of these ciliopathies 
should raise suspicion that TSC may also be part of this class of disorders. 
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Primary cilia are important in many aspects of neurodevelopment including 
establishment of progenitor populations, progenitor cell fate determination, and 
synaptic integration (Chizhikov et al. 2007; Han et al. 2008; Gorivodsky et al. 
2009; Kumamoto et al. 2012). As the primary cilium is crucial for normal neuronal 
development, it would be interesting to explore whether ciliary dysfunction is 
contributing to neurological phenotypes in TSC. Future work initially needs to 
identify whether changes in primary cilia are seen in both adult neurons as well 
as progenitor populations in TSC models. If elongated cilia are present in the 
brain as well, functional changes should be assessed. Cilia are specifically 
connected to neural plate polarization, neuronal migration, synapse formation 
and maintenance (Kumamoto et al. 2012; Higginbotham et al. 2012; 
Higginbotham et al. 2013). Changes in neuronal migration and synaptic function 
are thought to contribute to the pathogenesis of both autism and epilepsy. 
Therefore altered cilia may be an important link between mTOR signaling and 
these neurological manifestations of TSC. 
Additionally, abnormal cilia may also be responsible for some of the 
phenotypes seen in our patient derived iPSCs. While elongated cilia have not yet 
been observed in these lines, cilia may contribute to the cell proliferation 
abnormalities of these cells. In most non-dividing cells, cilia are present on the 
apical surfaces. However, in cells undergoing cell division, the primary cilium is 
present during gap phases of the cell cycle. The primary cilium must dissemble 
and release the basal body for cells to undergo mitosis and progress through the 
cell cycle (Quarmby and Parker 2005; Tucker, Scher, and Stiles 1979). Therefore, 
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alterations in cilia stability influence progression through the cell cycle and overall 
proliferation rates (Goto, Inoko, and Inagaki 2013). Changes in primary cilia 
during the gap phases in our stem cell lines may affect cell cycle progression and 
the increased proliferation we observe in TSC patient derived iPSCs. Future work 
should first identify whether TSC patient derived iPSCs have elongated primary 
cilia. Live cell imaging to observe cell cycle associated ciliogenesis and 
deciliation may prove insightful into the proliferation phenotypes. 
Finally, while loss of Tsc1 in the mouse kidney was restricted to the DCT, 
cystogenesis and altered mTORC1 activity was not restricted to this region. 
Future work should begin to explore the mechanism of non-cell-autonomous 
effects of altered mTOR signaling. Further evidence for non-cell-autonomous 
mechanisms in TSC have also been reported in studies using human samples 
and from a zebrafish model of TSC (Crino et al. 2010; Kim et al. 2011). Future 
directions will focus on how loss of mTOR affects neighboring cells, specifically 
identifying which soluble or cell surface molecules influence surrounding tissue. 
Alternatively, changes in the DCT may be causing decreased flow and increased 
pressure in more proximal portions of the nephron. In this case, it will be 
necessary to see if increased pressure or decreased flow secondary to 
cystogenesis in the DCT is indirectly injuring proximal tubules. The increase in 
diameter of the PCT and mTOR signaling changes may not be due to cellular 
signals from Tsc1 null cells but the result of a more global kidney injury. In vitro 
models of mixed populations of mutant and wild type primary cultured tubule 
epithelial cells as well as other non-TSC models of cystogenesis should be able 
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to address these possibilities. While rapamycin and other pharmacological 
inhibitors are useful for cell autonomous changes in mTORC1 signaling, newer 
therapies should consider potential non-cell-autonomous mechanisms when 
designing therapies to alter the course TSC pathologies. If soluble or cell-surface 
markers mediate these changes, targeting these molecules may protect 
neighboring tissue without a loss of heterozygosity from further damage and 
disease progression. 
 
TSC Patient Derived iPS Cells and Altered Survival and Pluripotency 
 
The experiments described in Chapter III established TSC patient derived 
iPS line specific phenotypes in cells heterozygous for TSC1 or TSC2. Previously 
we have shown that these heterozygous iPSCs are larger and proliferate more 
rapidly than controls, consistent with alterations in mTOR signaling. Here we 
have shown abnormalities in cell survival and maintenance of pluripotency as 
well. These phenotypes have provided many avenues for future experiments. 
First, the collective phenotypes seen in these cells all point to increased 
mTORC1 activity as a mechanistic mediator of their pathogenesis. Immunoblot 
analysis to assay mTORC1 activity has not been able to show changes in 
downstream targets of mTORC1 in these patient derived iPSCs. We hypothesize 
that the heterozygous nature of these cells results in subtle increases in 
mTORC1 signaling. To detect this, more sensitive techniques than immunoblot 
analysis are needed to measure mTORC1 activity such as ELISA or mass 
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spectrometry that allow highly accurate quantification of phospho-species of 
mTORC1 targets. These methods can be used to identify more precisely the 
activity of the mTOR kinase. Alternatively, alterations in these cells could be due 
to other non-mTOR related functions of the hamartin/tuberin complex. While the 
majority of work has implicated mTOR signaling as the major downstream target 
of the hamartin/tuberin complex there remains the possibility that this 
heterodimer has mTOR-independent functions as well. While not fully understood, 
there is some evidence that the hamartin/tuberin complex and Rheb can regulate 
p42/44 MAPK phosphorylation and B-Raf kinase activity independent of effects 
on mTOR activation (Karbowniczek et al. 2004). B-Raf and MAPK signaling are 
crucial for normal cellular differentiation (Rauen 2013). Hamartomas in TSC 
could be partially due to abnormalities in this pathway independent of mTOR 
signaling. The TSC patient derived iPSCs will be helpful in identifying whether B-
Raf and MAPK signaling is dysregulated by the heterozygosity of TSC1 or TSC2. 
Furthermore, more work needs to explore whether other, currently unidentified, 
non-mTOR mediated changes can result from dosage changes in either hamartin 
or tuberin.  
The alterations in pluripotency seen in these iPSCs deserve more 
exploration to determine the causative mechanism of this phenotype. Further 
experiments will support the observed increase in nuclear TFE3 in these cells. 
More complete separation of nuclear and cytoplasmic fractions should allow a 
clear analysis of this phenomenon. Increased nuclear TFE3 has been linked to 
increase mTORC1 activity (Betschinger et al. 2013). If increased mTORC1 
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activity is indeed responsible for the increased nuclear TFE3 in the heterozygous 
iPSCs, then inhibition of mTORC1 with rapamycin should return nuclear TFE3 
levels to normal. However, as discussed earlier, there remains the possibility of 
possible non-mTOR related functions of hamartin and tuberin. The connections 
between mTORC1 and the regulation of TFE3 localization are not yet well 
described. Future projects need to explore the kinases responsible and function 
of the phosphorylation of the upstream regulators of TFE3, such as FLCN and 
FNIP1/2. While there is evidence that FLCN is a substrate of mTORC1, it is 
unclear what role this phosphorylation event has on the function of this protein 
(Baba et al. 2006; Piao et al. 2009). Other parallel pathways or other kinases 
may also be affecting FLCN function. The functional consequences of increased 
pluripotency in these iPSCs should also be addressed. Time course experiments 
using directed differentiation should be done to identify the ability of these iPSCs 
to leave a pluripotent state, as well as the rate of progression through different 
developmental stages towards terminally differentiated cells. Alterations in 
pluripotency may cause an expansion of progenitor populations, or prevent 
maturation of functional neurons contributing to the neurological phenotypes in 
TSC. Finally, the resistance to differentiation of these cells should be explored in 
novel rodent models as well. In particular, examination of embryonic 
neurogenesis in animal models may identify changes in both the size of 
progenitor populations and altered rates of neuron production or synaptic 
integration. Increased pluripotency may also affect adult neurogenesis. To 
address this possibility, hippocampal and other adult progenitor populations 
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should be examined. The increased pluripotency of these cells could be a 
mechanism that generates the immature neurons and glia identified in cortical 
tuber tissue. Treatment that “resensitizes” these cells to normal differentiation 
signals may reduce the size of cortical tubers and ameliorate neurological 
symptoms.  
Altered cell survival in patient derived iPSCs implicates new pathways to 
explore as mediators of the pathogenesis of TSC. mTORC1 activation promotes 
cell survival, regulates cell cycle progression, and inhibits apoptosis in response 
to cellular stress (Park et al. 2011). Cell-cell contact promotes survival signals 
through ROCK1 to activate mTORC1 signaling (Arakawa-Takeuchi et al. 2010; 
Park et al. 2011). Increased survival in cell suspension is clearly increased in 
TSC1 or TSC2 null cells as well as our heterozygous iPSC lines. Further effort 
will identify whether the iPSCs have decreased activation of pro-apoptotic 
machinery in suspension. Additionally, the mechanism of increased cell survival 
in our iPSC should be explored to determine whether the heterozygosity of these 
cells is working through a ROCK1-mTORC1 axis or another parallel pathway. 
Improper regulation of cell survival may contribute to the pathogenesis of TSC 
through survival of abnormally differentiated cells, as well as persistence of 
normal cells usually undergoing apoptosis during neurodevelopment. As 
apoptosis is crucial in the pruning of excess neurons during development, these 
changes in cell survival can explain some of the alterations in patterning seen in 
TSC. Further elucidating the mechanisms of cell survival should help to better 
understand the development of cortical tubers. 
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Conclusion 
 
A better understanding of the molecular mechanism of TSC will provide 
new avenues for treatments, both for the disease itself as well as the broader 
categories of autism and epilepsy. Our rodent models and patient derived iPSCs 
allow the identification of downstream mediators of mTOR signaling disrupted in 
TSC. Elucidating the pathways regulated through mTOR such as protein 
translation, ciliary function, cell survival, and maintenance of pluripotency will not 
only help in the understanding of normal developmental process but also impact 
human health by identifying targets for pharmacological intervention. The TSC 
patient derived iPSCs provide an ideal opportunity for drug screening to identify 
small molecules that regulate the various aspects of this pathway. iPSCs can be 
used to identify molecules that correct the phenotypes of increased pluripotency 
and cell survival. Additionally, through directed differentiation towards neurons, 
small molecules can be tested at different time points during neurogenesis to 
identify therapeutic windows for treatment of TSC, as well as broader autism and 
epilepsy disorders. The generation of rodent models and TSC patient derived 
iPSCs are crucial to both understanding the mechanisms underlying the 
pathogenesis of TSC. Furthermore, these models provide a testable system for 
potential pharmaceutical treatments of the disease. Ultimately, the tissue specific 
phenotypes and underlying mechanisms identified in this work will hopefully lead 
to future treatments for TSC and its associated comorbidities. 
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